

Proposals of the [National Health Federation](#) for additional/revised Codex Nutrient Reference Values (NRVs) for labelling purposes

Introduction

The World Health Organization currently attributes one-third of all global deaths annually (15.3 million) to cardiovascular disease (332), and in 2000 over 6 million deaths occurred globally from cancer (333). Moreover, estimates predict that by 2020 the total number of cases of cancer will have increased by 73% in the developing world and by 29% in the developed world. (333). By 2020 it is estimated that chronic diseases will account for almost three-quarters of all deaths worldwide (561).

Faced with these statistics we are forced to question the wisdom of assuming that populations are healthy merely because they don't suffer from classical nutritional deficiency diseases such as scurvy, rickets, beri-beri or pellagra.

Current estimates of nutritional sufficiency, be they RDAs, AIs, EARs or NRVs, do not set nutritional intakes with the concept of optimum health in mind. They are simply estimates of the amounts of nutrients that healthy populations would require to maintain normal function and health and to avoid nutritional deficiency diseases. This approach, in our opinion, is highly flawed.

Given the increasing prevalence in our societies of conditions such as cardiovascular disease, cancer, obesity, diabetes, asthma, eczema, psoriasis, allergies, arthritis, high blood pressure, osteoporosis and depression, we believe that by definition our current system of nutritional values is no longer applicable.

Moreover, the consistency of evidence in the scientific literature clearly demonstrates that individuals who consume nutritional supplements have a lower risk of contracting serious disease - a position that has now been taken by two of the world's leading medical journals.

The Journal of the American Medical Association, for example, recently reversed its historical anti-vitamin policy by acknowledging that "it appears prudent for all adults to take vitamin supplements" (562). The article, authored by Robert H. Fletcher and Kathleen M. Fairfield from the Harvard School of Medicine, examined English-language articles about vitamins in relation to chronic diseases published between 1966 and 2002, and concluded that inadequate intake of several vitamins has been linked to the development of diseases including coronary heart disease, cancer, and osteoporosis.

Similarly, the April 9, 1998 issue of the New England Journal of Medicine featured an article entitled "Eat Right and Take a Multivitamin" that was based on a succession of positive studies showing the disease-prevention benefits resulting from the consumption of nutritional supplements (563).

We therefore consider that it would be a major step forward for global public health if the CCNFSDU were to finally accept and support the growing medical evidence that vitamin and mineral supplements prevent disease, promote optimum health and prolong lifespan.

Research has shown that there appears to be little risk to supplement users of experiencing adverse side effects due to excessive intakes of micronutrients (564).

We therefore propose the NRVs contained in this document as the minimum preventative intakes necessary to prevent disease, promote optimum health and prolong lifespan in the majority of people.

We also strongly believe that it is the duty of the CCNFSDU to make recommendations that advance nutritional welfare, prevent disease, promote optimum health and prolong lifespan , and that as such a general recommendation supporting the use of nutritional supplements would admirably fulfil all of these criteria.

Paul Anthony Taylor

29th March 2004

Vitamin A

Note: Includes provitamin A carotenoids that are dietary precursors of retinol. Given as retinol activity equivalents (RAEs). 1 RAE = 1 µg retinol, 12 µg beta-carotene.

Infants	
0-6 mo	400µg
7-12 mo	500µg
Children	
1-3 y	500µg
4-8 y	650µg
Males	
9-13 y	1050µg
14-18 y	1680µg
19-30 y	1800µg
31-50 y	1800µg
50-70 y	1800µg
> 70 y	1800µg
Females	
9-13 y	880µg
14-18 y	1350µg
19-30 y	1400µg
31-50 y	1400µg
50-70 y	1400µg
> 70 y	1400µg
Pregnancy	
≤ 18 y	1550µg
19-30y	1600µg
31-50 y	1600µg

Lactation	
≤ 18 y	1750µg
19-30y	1800µg
31-50 y	1800µg

Justification: The Helsinki Consultation in 1988 set a NRV for vitamin A of 800 microgrammes of retinol equivalent. In setting this figure the Consultation took into consideration the relation between carotene and the prevention of cancer, and stated that although this subject had not yet been resolved from the scientific point of view, it considered that this aspect might lead to an increase in the international recommended daily intakes in the future when new scientific data was available. Since 1988 however a large body of scientific evidence has clearly demonstrated that higher intakes of carotenes and/or preformed vitamin A are protective against the development of a number of cancers. (1-23).

Although some research exists to suggest that large doses of beta-carotene may possibly be capable of increasing the risk of lung cancer in smokers, we consider that in view of the many important health benefits to be obtained from higher intakes of carotenes it would be irresponsible for the CCNFSDU to recommend lower intakes for the entire population, as a means of protecting smokers, when official WHO policy is to substantially *reduce* the incidence of tobacco use. Tobacco, not carotene, is the main cause of lung cancer in smokers.

We also consider that the case for vitamin A being linked to birth defects has been overstated in some cases. In one study, for example, no birth defects were reported among 120 infants exposed to maternal intakes of vitamin A greater than 50,000 IU per day. (24). In addition, compared to the infants that were not exposed to high maternal doses of vitamin A the infants in this study that were exposed to high doses actually experienced a 50% *decreased* risk for birth defects. In fact, excessive dietary intake of vitamin A has been associated with birth defects in humans in fewer than 20 reported cases over the past 30 years. (25). Other data suggests that 30,000 IU of vitamin A per day should be considered safe for pregnant women. (26).

Vitamin B1

Infants	
0-6 mo	3mg
7-12 mo	6mg
Children	
1-3 y	8mg
4-8 y	13mg
Males	
9-13 y	23mg
14-18 y	37mg
19-30 y	40mg
31-50 y	40mg
50-70 y	40mg
> 70 y	40mg
Females	
9-13 y	23mg
14-18 y	37mg
19-30 y	40mg
31-50 y	40mg

50-70 y	40mg
> 70 y	40mg
Pregnancy	
≤ 18 y	38mg
19-30y	41mg
31-50 y	41mg
Lactation	
≤ 18 y	39mg
19-30y	42mg
31-50 y	42mg

Justification: There is now a wealth of research demonstrating that higher intakes of thiamin can improve general health and prevent disease. (27-49). This research also includes evidence that currently used assays may not be adequate to assess thiamine status, and that thiamine deficiency is underdiagnosed in life, in part because the classical clinical presentations are uncommon.

Furthermore, given that some of this research has shown that alcohol use, even moderate, interferes with thiamin metabolism (more so than with any other nutrient), we consider this increase in the NRV for thiamin to be both appropriate and essential.

No adverse effects associated with thiamin from food or supplements have been reported.

Vitamin B2

Infants	
0-6 mo	3mg
7-12 mo	6mg
Children	
1-3 y	8mg
4-8 y	13mg
Males	
9-13 y	23mg
14-18 y	37mg
19-30 y	40mg
31-50 y	40mg
50-70 y	40mg
> 70 y	40mg
Females	
9-13 y	23mg
14-18 y	37mg
19-30 y	40mg
31-50 y	40mg
50-70 y	40mg
> 70 y	40mg
Pregnancy	
≤ 18 y	38mg
19-30y	41mg
31-50 y	41mg
Lactation	

≤ 18 y	39mg
19-30y	42mg
31-50 y	42mg

Justification: Riboflavin has been shown to be protective against the development of degenerative diseases (62, 68), and studies have repeatedly demonstrated that worldwide intakes of riboflavin are below recommended values (50, 51, 52, 55, 59, 65).

Research has also shown that supplementation of riboflavin can improve health and wellbeing; either taken with other nutrients (53, 54, 60, 63, 69), or alone (56, 58); and that early detection of vitamin deficiency is difficult to diagnose due to the fact that it often occurs without any of the clinical signs of vitamin deficiency being present. (53).

Given that riboflavin intake has additionally been found to be inversely associated with coronary heart and vascular disease deaths and hospitalizations, as well as being a contributory factor in a number of other disease conditions when intake is insufficient (61, 64, 67), we consider this increase in the NRV for riboflavin to be entirely appropriate. (57).

Finally, we also note that a supplement of 15mg riboflavin has been shown to be insufficient to achieve normal biochemical indices in pregnancy (66), and that no adverse effects associated with riboflavin from food or supplements have been reported.

Niacin

Includes nicotinic acid amide, nicotinic acid (pyridine-3-carboxylic acid), and derivatives that exhibit the biological activity of nicotinamide.

Infants	
0-6 mo	15mg
7-12 mo	30mg
Children	
1-3 y	40mg
4-8 y	60mg
Males	
9-13 y	120mg
14-18 y	190mg
19-30 y	200mg
31-50 y	200mg
50-70 y	200mg
> 70 y	200mg
Females	
9-13 y	120mg
14-18 y	190mg
19-30 y	200mg
31-50 y	200mg
50-70 y	200mg
> 70 y	200mg
Pregnancy	
≤ 18 y	200mg
19-30y	210mg

31-50 y	210mg
Lactation	
≤ 18 y	205mg
19-30y	215mg
31-50 y	215mg

Justification: Increased consumption of niacin has been shown to prevent a range of diseases, illnesses and adverse health events; including heart attacks (70), migraine headaches (71), and cancer (72, 73). It has also been found to be effective in the treatment of schizophrenia (74-80), arthritis and joint disorders (81, 82), insulin-dependent diabetes (83), and hypoglycemia (84), and has repeatedly been shown to lower blood levels of cholesterol and triglycerides (85-93).

Pantothenic Acid

Infants	
0-6 mo	15mg
7-12 mo	30mg
Children	
1-3 y	40mg
4-8 y	60mg
Males	
9-13 y	120mg
14-18 y	190mg
19-30 y	200mg
31-50 y	200mg
50-70 y	200mg
> 70 y	200mg
Females	
9-13 y	120mg
14-18 y	190mg
19-30 y	200mg
31-50 y	200mg
50-70 y	200mg
> 70 y	200mg
Pregnancy	
≤ 18 y	200mg
19-30y	210mg
31-50 y	210mg
Lactation	
≤ 18 y	205mg
19-30y	215mg
31-50 y	215mg

Justification: Pantothenic acid and its natural derivatives have been shown to prevent and alleviate arthritis (94, 95); lower levels of cholesterol and other lipids (96-100); boost energy and athletic ability (101); and improve immune response (102).

Vitamin B6

Infants	
0-6 mo	3mg
7-12 mo	7mg
Children	
1-3 y	10mg
4-8 y	16mg
Males	
9-13 y	29mg
14-18 y	47mg
19-30 y	50mg
31-50 y	50mg
50-70 y	50mg
> 70 y	50mg
Females	
9-13 y	29mg
14-18 y	47mg
19-30 y	50mg
31-50 y	50mg
50-70 y	50mg
> 70 y	50mg
Pregnancy	
≤ 18 y	49mg
19-30y	52mg
31-50 y	52mg
Lactation	
≤ 18 y	50mg
19-30y	53mg
31-50 y	53mg

Justification: Studies in the elderly have repeatedly shown prevalences of B6 deficiency of around 25% (103). The prevalence of B6 deficiency, demonstrated biochemically, in population studies in developed countries, generally ranges from 9% in pre-school children (104), to 68% in pregnant women on low incomes (105). Studies in adults repeatedly show prevalences of B6 deficiency of around 25% (106).

Oral contraceptives have been shown to deplete levels of vitamin B6 (110-114). Not surprisingly then, vitamin B6 supplements can restore normal biochemical values (115, 116) and protect against metabolic imbalances in women taking these drugs (117).

Vitamin B6 supplements have also been shown to boost immunity in the elderly (107), reduce the risk of developing kidney stones in women (108), and relieve symptoms of pre-menstrual tension (109); as well as being effective in the treatment of autism (118), asthma (119), sickle cell anaemia (120), and morning sickness (121, 122). It has additionally been shown that patients with carpal tunnel syndrome are deficient in vitamin B6 (123), and that vitamin B6 is an effective treatment for this disorder (124, 125). Researchers have also demonstrated that levels of homocysteine, a risk factor for heart disease and stroke, can be reduced by supplements of vitamin B6, vitamin B12 and folic acid (126-129), and that levels of vitamins B6 are inversely related to homocysteine levels (126, 130). Levels of vitamin B6 are also inversely related to risk of lung cancer in men. (131).

Finally, we note that vitamin B6 is considered safe during pregnancy, and that it has been used in pregnant women without any evidence of foetal harm (132). Furthermore, it has also been found to have a positive effect upon pregnancy outcome (133), and to prevent certain types of seizures in infants (134).

Given all of the above evidence therefore, we consider this increase in the NRV for pyridoxine to be entirely appropriate.

Vitamin B12

Infants	
0-6 mo	7µg
7-12 mo	15µg
Children	
1-3 y	20µg
4-8 y	30µg
Males	
9-13 y	60µg
14-18 y	90µg
19-30 y	100µg
31-50 y	100µg
50-70 y	100µg
> 70 y	100µg
Females	
9-13 y	60µg
14-18 y	90µg
19-30 y	100µg
31-50 y	100µg
50-70 y	100µg
> 70 y	100µg
Pregnancy	
≤ 18 y	94µg
19-30y	104µg
31-50 y	104µg
Lactation	
≤ 18 y	97µg
19-30y	107µg
31-50 y	107µg

Justification: A number of population groups have been shown to have dietary intakes below the RDA for vitamin B12 (135-137), and vitamin B12 deficiency is estimated to affect 10%-15% of individuals over the age of 60 (138). Vitamin B12 deficiency becomes increasingly common with advancing age (139), and current findings in the scientific literature suggest that even subtle B12 deficiency is clinically significant (140). Frank deficiencies carry many health risks, and low serum levels of vitamin B12 are known to increase the risk of breast cancer in women (141), as well as being associated with a doubling of the risk of developing Alzheimer' s disease (142).

Vitamin B12, when taken with folic acid, has been shown to be effective in the treatment of osteoarthritic hands (143), and has been found to reduce the incidence of bronchial squamous metaplasia, a precancerous change - even in heavy smokers (144-145). It has also been

demonstrated to be capable of curing sciatica (146), reversing some of the effects of chronic nitrous oxide exposure (147), and when taken with the amino acid carnitine, has been shown to be effective in the treatment of anorexia nervosa (148).

There is now abundant evidence that high levels of homocysteine are associated with an increased risk of developing cardiovascular disease (149-161), and that serum levels of vitamin B12 are inversely related to homocysteine levels (162-163). It has also been shown that a deficiency of vitamin B12 can raise levels of homocysteine (164), and that supplementation with combinations of folic acid, vitamin B6 and vitamin B12 is an effective means to reduce elevated levels of homocysteine (165-168). Raised levels of homocysteine have also been shown to increase the risk of developing Alzheimer' disease (169).

Observational studies have found that as many as 30% of patients hospitalized for depression are deficient in vitamin B12 (170), and that vitamin B12 deficient women over the age of 65 are twice as likely to be severely depressed as non-deficient women (171). Indeed, there is also epidemiological evidence that even a moderate deficiency of vitamin B12 may lead to mental illness (172).

Supplementation of vitamin B12 has been shown to have a significant positive effect upon memory (173), and to improve emotional state, even in the absence of deficiency (174). Studies have additionally shown that vitamin supplements that include vitamin B12 are associated with better performance on difficult visuospatial and abstraction tests (175), and that regular use of such supplements confers some degree of protection against vitamin B12 deficiency in older adults (176).

Finally, researchers have also shown that vitamin B-12 dependency disorders are common and that they are neglected by the medical profession (174), and that the cut-off point of serum concentration should be raised, because many elderly people with "normal" serum vitamin B12 concentrations are metabolically deficient in cobalamin (177).

We therefore have no hesitation in recommending the above increase in the NRV for vitamin B12.

Folate

Infants	
0-6 mo	65µg
7-12 mo	120µg
Children	
1-3 y	155µg
4-8 y	260µg
Males	
9-13 y	465µg
14-18 y	750µg
19-30 y	800µg
31-50 y	800µg
50-70 y	800µg
> 70 y	800µg
Females	
9-13 y	465µg
14-18 y	750µg

19-30 y	800µg
31-50 y	800µg
50-70 y	800µg
> 70 y	800µg
Pregnancy	
≤ 18 y	780µg
19-30y	830µg
31-50 y	830µg
Lactation	
≤ 18 y	815µg
19-30y	865µg
31-50 y	865µg

Justification: Many studies have shown that an inadequate intake of folate is relatively common (178-187), and research over the past 30 years has demonstrated a relationship between folic acid deficiency and psychopathology (188). Neuropsychiatric diseases secondary to folate deficiency may include dementia, schizophrenia-like syndromes, insomnia, irritability, forgetfulness, endogenous depression, organic psychosis, peripheral neuropathy, myelopathy, and restless legs syndrome (189). Low serum folate levels are also known to be associated with a doubling of the risk of developing Alzheimer' disease (142).

Higher levels of folate however have been shown to be related to a lower incidence of nuclear lens opacities, which are associated with the development of cataracts (193).

Data from the Nurses' Health Study conducted at the Harvard Medical School found that long-term supplementation with folic acid reduces the risk of colon cancer in women by 75% (190). Indeed, there is an inverse relationship between the intake of folate and the risk of developing various esophageal and gastric cancers (191), and folic acid is known to be effective in the treatment of atrophic gastritis, where it prevents or reverses precancerous lesions (192). Furthermore, folic acid taken with vitamin B12 has been found to be effective in the treatment of osteoarthritic hands (143), and in the reduction of the incidence of bronchial squamous metaplasia (a precancerous change) - even in heavy smokers (144-145).

Folic acid supplements have also been shown to reduce blood pressure in smokers (194), and research has established that supplementing the diet with vitamins C, E, B6 and folate is conducive to the prevention of cardiovascular disease (195). In this respect there is now abundant evidence that high levels of homocysteine are associated with an increased risk of developing conditions such as cardiovascular disease (149-161) and Alzheimer' disease (169), and studies have shown that supplementation with combinations of folic acid, vitamin B6 and vitamin B12 is an effective means to reduce elevated levels of homocysteine (165-168).

High levels of homocysteine accompanied by low levels of folate are also known to be risk factors for heart attack (197). This link has been further established through research showing that folic acid supplements can reduce levels of homocysteine (198) and hence protect against heart attacks (199). As such it is noteworthy that children with a family history of CVD have been found to have lower intakes of folate, lower serum folate levels, and higher levels of homocysteine (196), and that supplements of folic acid, vitamin B6 and vitamin B12 have even been shown to reduce the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients (200).

Scientific evidence has now clearly demonstrated that women given folic acid supplements during pregnancy have a lower incidence of delivering babies with neural tube birth defects (201-203),

and researchers have therefore emphasised the importance of all fertile women, regardless or not of whether they are intending to become pregnant, taking daily multivitamins that contain 400µg (0.4 mg) of folic acid (204). Folic acid-containing multivitamins have additionally been shown to reduce the risk of gestational hypertension (205).

It is now known that in the elderly even moderate folate depletion will only respond to an intake of folate in excess of the RDA (206). Researchers have also shown that folic acid supplements are more effective than increased dietary folate intake in elevating serum folate levels (207). Indeed, the use of nutritional supplements is particularly beneficial in promoting adequate intakes of folate in women aged 18-50 years (208), and research has made it clear that people who do not take folic acid supplements are at increased risk for functional folate deficiency (209).

Given that research has already shown that the current RDA for folate is insufficient to attain optimal homocysteine levels (210), and that micronutrients both prevent cancer and delay aging (211), there can now be little doubt that the Helsinki Consultation's recommendation to reduce the NRV for folate from 400µg to 200µg was a step in the wrong direction.

Biotin

Infants	
0-6 mo	60µg
7-12 mo	120µg
Children	
1-3 y	155µg
4-8 y	260µg
Males	
9-13 y	465µg
14-18 y	750µg
19-30 y	800µg
31-50 y	800µg
50-70 y	800µg
> 70 y	800µg
Females	
9-13 y	465µg
14-18 y	750µg
19-30 y	800µg
31-50 y	800µg
50-70 y	800µg
> 70 y	800µg
Pregnancy	
≤ 18 y	780µg
19-30y	830µg
31-50 y	830µg
Lactation	
≤ 18 y	810µg
19-30y	860µg
31-50 y	860µg

Justification: There is good evidence that biotin deficiency is by no means uncommon (212-216). Biotin is essential for numerous biochemical, dermatological and neurological processes, and

long-term auditory and visual complications can result from a deficiency in this nutrient (217, 218). Biotin deficiency has also been found to cause mitochondrial decay with oxidant leakage leading to accelerated aging and neural decay (219).

Biotin has furthermore been shown to improve glucose metabolism (220-223), and research suggests that biotin supplements may be particularly useful in the prevention of diabetes (224). High doses of biotin may also synergize with chromium picolinate to enable a definitive nutritional therapy for type II diabetes, and may likewise be useful in the prevention and management of gestational diabetes, as well as being an aid to glycemic control in type I patients. (225). Indeed, drugs such as metformin and troglitazone, which are expensive and require regular physician monitoring to avoid potentially dangerous sideeffects, would appear to be less practical options from costeffectiveness, convenience and safety standpoints, given the fact that the population at risk for diabetes is huge. (226).

Finally, biotin supplements have also been found to effect a marked improvement in patients suffering from severe diabetic peripheral neuropathy (227), and have been shown to significantly increase the growth rate and strength of hair in children (228).

Worldwide, the number of cases of diabetes is estimated to be around 150 million, and is expected to double by 2025 (229). Because of the wealth of research demonstrating the ability of biotin supplements to both prevent diabetes and improve glucose metabolism we have no hesitation in recommending the above NRVs.

Vitamin C

Infants	
0-6 mo	200mg
7-12 mo	400mg
Children	
1-3 y	600mg
4-8 y	1000mg
Males	
9-13 y	1750mg
14-18 y	2800mg
19-30 y	3000mg
31-50 y	3000mg
50-70 y	3000mg
> 70 y	3000mg
Females	
9-13 y	1750mg
14-18 y	2800mg
19-30 y	3000mg
31-50 y	3000mg
50-70 y	3000mg
> 70 y	3000mg
Pregnancy	
≤ 18 y	2900mg
19-30y	3100mg
31-50 y	3100mg
Lactation	

≤ 18 y	3000mg
19-30y	3200mg
31-50 y	3200mg

Justification: Studies have shown that several population groups have an inadequate intake of vitamin C, and that deficiencies of ascorbic acid are far more prevalent than is commonly believed (230-241). Moreover, patients suffering from dementia (242), epilepsy (243), preeclampsia (244, 245), gallbladder disease (246), schizophrenia (247, 248), coronary artery disease (249-253), cerebral vascular disease (254), esophageal, stomach and colorectal cancers (255, 256) and gastric cancer (257), have all been found to have significantly lower levels of vitamin C than are found in normal healthy people.

Similarly, the risk of stroke has been shown to increase significantly with a decreased intake of vitamin C (258), and low levels of ascorbic acid are implicated in the development of gastric cancer (259-261), periodontal disease (262), and cardiovascular disease (263). A high intake of ascorbic acid, on the other hand, has been found to be protective against the development of gastric cancer (264-269, 292-296), as well as cancers of the esophagus (270), uterus (290), oral cavity, stomach, pancreas, cervix, rectum, lung (291), breast (291, 298, 299), ovaries (310), and others (271). In this respect it is interesting to note that megadoses of vitamin C and other nutrients have been shown to significantly reduce the recurrence of tumours in patients with bladder cancer (297), and that male smokers with a high intake of vitamin C have been shown to have a lower risk of cancer than male smokers with a lower intake of vitamin C (300).

Hospital patients with low levels of ascorbic acid have a greater frequency of postoperative complications, and administering ascorbic acid until blood levels returned to normal has been proven to prevent postoperative complications (327). Other researchers have demonstrated that a mixture of vitamins C, E and A also dramatically reduces the postoperative complication rate (328).

People with the highest levels of vitamin C have also been found to have a significantly lower incidence of nuclear opacities. In fact, it has been found that the longer the duration that vitamin C supplements are taken for the lower is the prevalence of nuclear opacities. This has led researchers to conclude that vitamin C plays a strong role in preventing nuclear opacities (272). Other studies recommend the use of vitamin C and other antioxidant supplements in the prevention of age-related cataract and macular degeneration (273), and research also shows that that ascorbic acid can protect the cornea from ultraviolet radiation (274).

Research has shown that a high dietary intake of vitamin C and vitamin E may lower the risk of Alzheimer disease (329). Other researchers have confirmed this, and have demonstrated that long-term supplement users of vitamin E with vitamin C have significantly better mental performance than do people who have never used vitamin E or vitamin C supplements (331), and that vitamins C and E may prevent dementia and improve cognitive functioning in later life (330).

Studies have also confirmed that vitamin C has a protective effect against the development of coronary heart disease (275, 276), and that vitamin C is beneficial in preventing the advancement of arteriosclerosis in heart transplant patients (277). Indeed, researchers have shown that human cardiovascular disease is the direct consequence of the inability of man to synthesize ascorbate in combination with insufficient intake of ascorbate in the modern diet. Since ascorbate deficiency is the common cause of human CVD, ascorbate resupplementation is the universal treatment for this disease (278). As such, the therapeutic use of vitamin C and other nutrients may well pave the way towards a new therapeutic goal, namely, the noninvasive reversal of existing

cardiovascular disease with nutritional supplements (279). In that respect it is now increasingly clear that vitamin C should be used in the treatment of coronary arterial disease patients, and those with heart attacks, strokes, or hypertension (301).

A daily dose of 2700 mg of Vitamin C, when taken with other nutrients, has been shown to halt the progression of early coronary atherosclerosis (280), and other researchers have similarly found that the combination of vitamin C and vitamin E can slow the advancement of atherosclerosis (281). Furthermore, a review of studies of vitamins A, C and E and cardiovascular disease found significant evidence to support the supplementation of these vitamins to lower the risk of death from this illness, and concluded that diabetics, smokers and those with hypertension would all benefit from taking supplemental vitamin C (282). As such, it is now clear that the progression of early stages of coronary calcifications can be stopped or limited by the synergistic effect of vitamins and essential nutrients (283, 289), and that supplementing the diet with nutrients including vitamins C, E, B6 and folate is conducive to the prevention of cardiovascular disease (284). In this respect it is also interesting to note that some researchers particularly recommend dietary supplementation of vitamin C and E in Northern Europe, where cardiovascular disease is most prevalent (285).

Deaths from stomach cancer and cardiovascular disease and cerebrovascular disease are all associated with low levels of vitamin C (286); in fact it has been demonstrated that mortality for all causes of death decreases strongly with an increased intake of supplemental vitamin C (287). A study of 8,453 Americans' serum ascorbic acid (SAA) levels and mortality rates from disease, for example, found that those with a normal to high level of SAA had a 21%-25% lower risk of dying from cardiovascular disease, and that they had a 25%-29% decrease in risk of mortality from all causes compared to those with low levels of SAA (288).

Vitamin C supplements have also been shown to improve the body's ability to metabolize glucose and lipids and as such are seen as being beneficial to those with Type II diabetes (302). Similarly, people with higher levels of vitamin C have been found to have a lower incidence and risk of hyperglycemia (303).

Critically ill surgery patients have been shown to be significantly less likely to experience organ failure, spend less time using mechanical ventilation and have shorter times in intensive care units when they are given supplements of vitamin C and vitamin E (304).

Vitamin C supplements have been shown to be an effective treatment for hypertension, both in non-diabetics (305-308), and in diabetics (309), and have been found to reduce muscle soreness and improve muscle function after exercise (317, 318).

Research has also demonstrated the ability of higher doses of vitamin C to delay bone loss (311), and to increase bone density (312). Similarly, an increased intake of vitamins C and E has been shown to reduce the risk of hip fractures (313).

Studies have also found that the duration and severity of colds can be decreased by an increased intake of vitamin C (314, 315), and that doses of vitamin C between 500-2000mg improve antioxidant protection (316).

Some researchers have argued for higher intakes of vitamin C to be recommended for populations chronically exposed to air pollutants (such as ozone), cigarette smoking, or those doing vigorous exercise (319). Other studies have made similar recommendations for people who are exposed to passive smoking (320, 321). Indeed, it has been shown that high doses of vitamin

C can reduce or eliminate the negative effect that smoking has on blood flow (322), and that vitamin C supplements can protect against the cardiovascular problems caused by cigarette smoke inhalation (323). In this respect it is also interesting to note that vitamin C supplements have been shown to significantly reduce cholesterol, LDL-C and triglycerides, as well as increase serum HDL (324).

Researchers also recommend that people who are smokers, diabetics, pregnant, users of antibiotics, people who ingest alcohol, and users of contraceptives all need to supplement with vitamin C. (325). Indeed, vitamin C is depleted in women who use oral contraceptives, which may result in cardiac problems and thrombosis. (326). Since vitamin supplements are routine for pregnancy, they should also be routine for the pseudopregnancy of oral contraception (326).

Finally, we note that the World Health Organization currently attributes one-third of all global deaths annually (15.3 million) to cardiovascular disease (332), and that in 2000 over 6 million deaths occurred from cancer (333). Moreover, estimates predict that by 2020 the total number of cases of cancer will have increased by 73% in the developing world and by 29% in the developed world. (333). Given therefore the proven safety and efficacy of ascorbic acid in the prevention and treatment of both cardiovascular disease and cancer, we have no hesitation in recommending the above NRVs for this nutrient.

Vitamin D

Note: 1µg calciferol = 40 IU vitamin D.

Infants	
0-6 mo	5µg
7-12 mo	5µg
Children	
1-3 y	5µg
4-8 y	6.5µg
Males	
9-13 y	12µg
14-18 y	18µg
19-30 y	20µg
31-50 y	20µg
50-70 y	20µg
> 70 y	20µg
Females	
9-13 y	12µg
14-18 y	18µg
19-30 y	20µg
31-50 y	20µg
50-70 y	20µg
> 70 y	20µg
Pregnancy	
≤ 18 y	20µg
19-30y	20µg
31-50 y	20µg
Lactation	
≤ 18 y	20µg

19-30y	20µg
31-50 y	20µg

Justification:

Nowadays, severe deficiency of vitamin D is not a common finding in most developed countries. However, the prevalence of vitamin D insufficiency is relatively high and it can contribute to the lowering of bone mass in osteoporosis risk populations (334). In this respect it is important to note that Vitamin D deficiency can occur without any symptoms, and that if symptoms are present it indicates severe deficiency (349). Moreover, serum calcium and phosphorus values do not often predict the existence of deficiency (349).

A decrease in bone mineral density is the most important cause of fracture (335). Among other factors, Calcium and vitamin D deficiencies are important risk factors for a decrease in bone mineral density, and can consequently induce osteoporosis (335). In this respect it is interesting to note that the high prevalence of vitamin D deficiency in healthy elderly people in southern European countries increases the risk of osteoporotic fractures in these populations to levels above those anticipated for the general elderly population of the European community (335). As such, the ageing of the European population will double the number of osteoporotic fractures over the next 50 years unless adequate preventative measures are undertaken (335).

Research assessing the cost implications for a preventive treatment strategy for institutionalised elderly women found that the incidence of hip and other fractures was reduced by vitamin D and calcium supplements, and concluded that such strategies are cost saving (336). The doses given in this study were 1200 mg/day calcium and 20µg (800 IU) daily of vitamin D, and the data used in the research was collected from studies conducted in seven European countries (336).

Other research concurs that a daily dose of 20µg (800 IU) of vitamin D (or the equivalent 2500µg/100,000 IU given three times per year) reduces the frequency of both falls (337) and fractures (338-340). Moreover, research has shown that severe vitamin D deficiency is present in virtually all elderly institutionalized subjects, and that as such, routine vitamin D supplementation is warranted for such people (341).

Studies also suggest that a daily supplement of 10µg (400 IU) is helpful in maintaining an adequate concentration of vitamin D in infants (342), and that vitamin D supplementation during infancy is associated with higher bone mineral mass in prepubertal girls (343).

Research has also shown that most cases of colon cancer may be prevented with an intake of vitamin D in the range of 20µg (800 IU) per day, and epidemiological data suggest that such an intake may additionally be associated with enhanced survival rates among breast cancer cases (344). Other evidence from diverse areas of study - epidemiologic, molecular, genetic, cellular, animal models, and clinical trials - suggests that vitamin D may be an effective preventive agent against prostate cancer (345).

Dietary supplementation of vitamin D is also associated with reduced risk of type1 diabetes, and children who take a 20µg (2000 IU) dose of vitamin D daily have been shown to have a lower risk of developing the disease than children who do not (346).

Women with the highest vitamin D intake from supplements (10µg/400 IU or more per day) have been shown to be 40 percent less likely to develop multiple sclerosis than those women who do not use supplements (347). Similarly, women who consume vitamin D in both supplement and

food form have also been shown to have a lower risk of developing multiple sclerosis; whereas women who derive their intake of this vitamin from food only do not experience a reduced risk of developing the disease (347). In addition, patients already suffering from multiple sclerosis who are given supplements of vitamin D, calcium and magnesium have been shown to have a decreased rate of relapse (348).

Research has also shown that vitamin D deficiency exists in patients with tuberculosis, and that it is possibly a cause rather than an effect of this disease (349). Given the fact therefore that the incidence of this disease is currently increasing in many countries, there exists an urgent need for effective, affordable preventative measures to be instigated at the earliest opportunity.

Finally, we are of the opinion that the alleged dangers of vitamin D supplements have been exaggerated in many cases, as single doses ranging from 200,000 units to over 500,000 units have been given to infants both orally and by injection without any ill effects. (350). Moreover, the weight of evidence shows that the currently accepted, no observed adverse effect limit of 2,000 IU per day is too low by at least 5-fold (351). One hour of total-body sun exposure easily provides the equivalent of 10,000 IU of vitamin D, for example (351); clearly, many people get this on a regular basis without experiencing toxicity symptoms. Doses of 15000µg (600,000 IU) of vitamin D have also been given to pregnant women in the 7th and 8th months of pregnancy without evidence of harm (352).

Vitamin E

Infants	
0-6 mo	30 IU
7-12 mo	60 IU
Children	
1-3 y	80 IU
4-8 y	130 IU
Males	
9-13 y	230 IU
14-18 y	370 IU
19-30 y	400 IU
31-50 y	400 IU
50-70 y	400 IU
> 70 y	400 IU
Females	
9-13 y	230 IU
14-18 y	370 IU
19-30 y	400 IU
31-50 y	400 IU
50-70 y	400 IU
> 70 y	400 IU
Pregnancy	
≤ 18 y	385 IU
19-30y	415 IU
31-50 y	415 IU
Lactation	
≤ 18 y	400 IU
19-30y	430 IU

Justification: The World Health Organization currently attributes one-third of all global deaths annually (15.3 million) to cardiovascular disease (332), and patients with coronary artery disease have been shown to have significantly lower blood levels of vitamin E than normal healthy people. (249).

Studies have demonstrated that vitamin E supplements are effective in the treatment of cardiovascular disease (353-355), and that the combination of vitamin E and vitamin C can slow the advancement of atherosclerosis (281). Furthermore, a review of studies of vitamins A, C and E and cardiovascular disease found significant evidence to support the supplementation of these vitamins to lower the risk of death from this illness (282). As such, it is now clear that the progression of early stages of coronary calcifications can be stopped or limited by the synergistic effect of vitamins and essential nutrients (283, 289), and that supplementing the diet with nutrients including vitamins E, C, B6 and folate is conducive to the prevention of cardiovascular disease (284). In this respect it is also interesting to note that some researchers particularly recommend dietary supplementation of vitamin E and C in Northern Europe, where cardiovascular disease is most prevalent (285).

Vitamin E therapy has also been shown to reduce arterial blockage in patients suffering from intermittent claudication (356, 357), and recent research has indicated that it normalizes high blood pressure (358-360). Vitamin E also promotes collateral circulation; consequently offering great benefits to diabetes patients (361).

A recent study looked at patients with colon cancer who received a daily dose of 750 mg of vitamin E during a period of 2 weeks. The researchers found that supplementation with high doses of dietary vitamin E produced a significant improvement in the immune functions of these patients, all of whom had advanced cancer. It is especially notable that this improvement was achieved in only two weeks (362).

Other research suggests that vitamin E supplementation also improves immune function in healthy elderly people (366, 367).

Research has additionally shown that a high dietary intake of vitamin E and vitamin C may lower the risk of Alzheimer disease (329). Other researchers have confirmed this, and have demonstrated that long-term supplement users of vitamin E with vitamin C have significantly better mental performance than do people who have never used vitamin E or vitamin C supplements (331), and that vitamins E and C may prevent dementia and improve cognitive functioning in later life (330). Similarly, a Columbia University study reported that the progression of Alzheimer's disease was significantly slowed in patients taking high daily doses (2,000 IU) of vitamin E for two years (363).

In another study, 400 IU of vitamin E per day given to epileptic children for several months reduced the frequency of seizures in most of them by over 60 percent, whilst half of them had a 90 to 100 percent reduction in seizures. This study is also notable for the fact that the researchers specifically stated that the children suffered no adverse side effects from the vitamin E treatment (364). Similarly, preterm infants given 100 mg of vitamin E per kilogram body weight (as a preventative treatment for incubator oxygen retina damage - a major cause of retrolental fibroplasia and subsequent blindness in premature infants) suffer no detrimental side effects from such therapy. (365).

It is also notable that a statistical analysis of published clinical results showed as early as 1940 that vitamin E supplements reduce the rate of recurrent miscarriage (368).

An increased intake of vitamins E and C has been found to reduce the risk of hip fractures (313), and researchers have also demonstrated that a mixture of vitamins E, C and A dramatically reduces the postoperative complication rate (328). Similarly, critically ill surgery patients have been shown to be significantly less likely to experience organ failure, spend less time using mechanical ventilation and have shorter times in intensive care units when they are given supplements of vitamin E and vitamin C (304).

Finally, research has shown that healthy centenarians have high levels of both vitamin E and vitamin A, and that this seems to be important in guaranteeing their extreme longevity (369).

We also note that the 2000 report by the Institute of Medicine of the National Academy of Sciences acknowledges that 1,000 mg (1,500 IU) vitamin E is a "tolerable upper intake level . . . that is likely to pose no risk of adverse health effects for almost all individuals in the general population."

Vitamin K

Infants	
0-6 mo	45µg
7-12 mo	90µg
Children	
1-3 y	120µg
4-8 y	190µg
Males	
9-13 y	350µg
14-18 y	560µg
19-30 y	600µg
31-50 y	600µg
50-70 y	600µg
> 70 y	600µg
Females	
9-13 y	350µg
14-18 y	560µg
19-30 y	600µg
31-50 y	600µg
50-70 y	600µg
> 70 y	600µg
Pregnancy	
14-18 y	580µg
19-30 y	620µg
31-50 y	620µg
Lactation	
14-18 y	605µg
19-30 y	645µg
31-50 y	645µg

Justification: Research using healthy adults aged 19-36 years who were given vitamin K supplements has shown that a daily phylloquinone intake of approximately 1000µg is required to maximally gamma-carboxylate circulating osteocalcin (370), and that a diet low in vitamin K1 can result in a functional subclinical deficiency of vitamin K (decreased urinary gamma-carboxyglutamic acid excretion) without affecting blood coagulation (371). Current estimates suggest that the dietary intake of vitamin K is in the range 124-375 µg /d in a European population (372).

Studies have repeatedly shown that higher intakes of vitamin K reduce the risk of hip fracture (373, 374) and that low intakes may increase the risk of hip fracture in women (375). This data supports the case for a reassessment of the vitamin K requirements that are based on both blood coagulation *and* bone health (375).

Low dietary vitamin K intake is also associated with low bone mineral density in women (376), and evidence from observational studies and first intervention trials indicate that vitamin K intakes much higher than the current recommendations improve both biochemical markers of bone formation and bone density (377). In deed, the mechanistic data as well as the observational data and the results of the first controlled clinical trials in humans point to a beneficial effect of additional intakes of vitamin K in bone health (377).

Supplements of vitamin K (containing 45mg of menatetrenone) have been shown to promote bone formation in postmenopausal women when taken for a period of 48 weeks (378), and therapy combining vitamin K(2) and D(3) has been shown to be useful for increasing vertebral bone mass in postmenopausal women (379). Similarly, research findings indicate that the combined administration of vitamin D3 and vitamin K2 appears to be useful in increasing the bone mineral density of the lumbar spine in postmenopausal women with osteoporosis (380), and that vitamin K (as menatetrenone) may be beneficial in the prevention of bone loss in patients with anorexia nervosa (381).

Vitamin K (as menatetrenone) has also been shown to reduce the risk of hip fracture in elderly female Parkinson's disease patients (382). Significant reduction in bone mineral density occurs in patients with Parkinson' s disease, resulting in an increasing risk of hip fracture, especially in elderly women. (382).

Research also suggests that it would be prudent to consider routine vitamin K supplementation in patients with cystic fibrosis, severe noncholestatic and cholestatic liver disease, major small-bowel resection, and pancreatic insufficiency or lung disease necessitating frequent use of antibiotics (383). Patients with Crohn's disease have also been found to have low serum levels of vitamin K, and as such are at particular risk of osteoporosis (384).

Studies have demonstrated that oral vitamin K is as effective as injectable Vitamin K in newborns, and researchers are now recommending its usage to reduce the complications and costs of parenteral therapy (385). Other data has confirmed the effectiveness of oral vitamin K given to newborns in reducing infant mortality and morbidity from bleeding disorders such as intracranial hemorrhage (386). Indeed, additional research suggests that supplementation of infants with vitamin K is highly advisable, and that increments of vitamin K during pregnancy and lactation should also be recommended (387). In this respect it is interesting to note that maternal vitamin K supplementation can maintain the vitamin K status of infants throughout the late neonatal period and prevent an onset of vitamin K-deficient hemorrhage (388).

Finally, research has also shown that low dietary vitamin K intake is associated with an increased risk of aortic calcification (389), and that vitamin K may play an important role in the acute insulin response in glucose tolerance (390).

Boron

Based upon the knowledge that we have at this time, we consider that the science suggests an optimal intake of 1.5-3mg for men and women aged 18 years and above, and that dietary boron is sufficiently important to be considered essential in human beings.

Justification: The daily intake of boron in humans has been estimated to range from 0.3-41 mg. The wide range is due to the variation of the analytical methods used and differences in the soil content of boron (464).

Dietary boron influences the activity of many metabolic enzymes, as well as the metabolism of steroid hormones and several micronutrients, including calcium, magnesium, and vitamin D (465).

Research shows that a boron supplement of 3 mg/day markedly reduces the urinary excretion of calcium and magnesium in post-menopausal women (466).

Because boron deprivation causes changes similar to those seen in women with postmenopausal osteoporosis, this element is apparently needed for optimal calcium metabolism and is thus needed to prevent the excessive bone loss which often occurs in postmenopausal women and older men (467).

The elevation of endogenous estrogen as a result of supplementation suggests a protective role for boron in atherosclerosis (468).

When contrasted with the high boron intake, low dietary boron results in significantly poorer performance on tasks emphasizing manual dexterity; eye-hand coordination; attention; perception; encoding and short-term memory; and long-term memory. Data indicates that boron may play a role in human brain function and cognitive performance, and provides additional evidence that boron is an essential nutrient for humans (469).

Evidence suggests boron is a safe and effective treatment for some forms of arthritis. Epidemiologic evidence shows that in areas of the world where boron intakes usually are 1.0 mg or less/day the estimated incidence of arthritis ranges from 20 to 70%, whereas in areas of the world where boron intakes are usually 3 to 10 mg, the estimated incidence of arthritis ranges from 0 to 10%. Experimental evidence from a double-blind placebo-boron supplementation trial with 20 subjects with osteoarthritis showed a significant favorable response to a 6mg boron/day supplement, in that 50% of subjects receiving the supplement improved compared to only 10% receiving the placebo. This data indicates that boron is an essential nutrient for healthy bones and joints (470).

Finally, men who ingest the greatest amount of boron have been shown to be 64% less likely to develop prostate cancer compared to men who consumed the least amount of boron (471).

Calcium

Infants	
0-6 mo	210mg
7-12 mo	270mg
Children	
1-3 y	500mg
4-8 y	800mg
Males	
9-13 y	1300mg
14-18 y	1300mg
19-30 y	1000mg
31-50 y	1000mg
50-70 y	1200mg
> 70 y	1200mg
Females	
9-13 y	1300mg
14-18 y	1300mg
19-30 y	1000mg
31-50 y	1000mg
50-70 y	1200mg
> 70 y	1200mg
Pregnancy	
≤ 18 y	1300mg
19-30y	1000mg
31-50 y	1000mg
Lactation	
≤ 18 y	1300mg
19-30y	1000mg
31-50 y	1000mg

Justification: The above figures are the current US NRVs for calcium (391), and we broadly concur with both the US supporting data and with other research which suggests that the daily consumption of calcium in the diet should, optimally, be at least 1200 mg/day (392).

Copper

Infants	
0-6 mo	200µg
7-12 mo	290µg
Children	
1-3 y	390µg
4-8 y	645µg
Males	
9-13 y	1160µg
14-18 y	1870µg
19-30 y	2000µg
31-50 y	2000µg
50-70 y	2000µg
> 70 y	2000µg
Females	
9-13 y	970µg

14-18 y	1570µg
19-30 y	1680µg
31-50 y	1680µg
50-70 y	1680µg
> 70 y	1680µg
Pregnancy	
≤ 18 y	1670µg
19-30y	1780µg
31-50 y	1780µg
Lactation	
≤ 18 y	1770µg
19-30y	1880µg
31-50 y	1880µg

Justification: Several national food surveys in the United States have revealed marginally to moderately low contents of copper in the typical American diet (393), and the dietary intake of copper has been shown to be below the recommended daily allowance in several different population groups. (394-396).

Metabolic balance studies have demonstrated that daily copper losses are approximately 1.3 mg/day (397). In order to remain in copper balance, the average adult male must consume a diet that contains at least 2 mg copper/day. (397). However, some research suggests that up to eighty-one per cent of people consume less than 2mg of copper in their daily diets (398), and that a marginal deficiency of this trace element exists in up to 62% of people suffering from hypertension (399). In this respect it is interesting to note that supplementation with 5mg of copper per day has been shown to decrease both systolic and diastolic blood pressure in patients with mild stable hypertension (399).

Research has shown that the recovery from mild copper depletion may require more aggressive intervention than 2mg per day of copper taken for 35 days (400), and a review of studies of experimental copper deprivation conducted in adult humans indicated that 2.6 mg of copper per day taken for periods of up to 42 days is similarly sufficient for recovery from copper deprivation (401). Studies from animal models and in human volunteers have permitted to construct a provisional continuum of acceptable intakes of copper that would avoid copper deficiency and/or toxicity: acceptable intakes may vary between 10 and 50µg/kg body weight (402).

Men and women fed diets close to 1 mg of copper per day, amounts quite frequent in the United States, responded with reversible, potentially harmful changes in blood pressure control, cholesterol and glucose metabolism, and electrocardiograms (403). Copper deficiency is also known to impair cell-mediated immunity (408).

Numerous anatomical, chemical and physiological similarities between animals deficient in copper and people with ischemic heart disease have been noticed (403, 406), and a correlation has been established between low intake of copper and prevalence of ischemic heart disease, dyslipoproteinemia, arterial hypertension and excessive body mass (404). Dietary copper deficiency may also impair cardiovascular health by contributing to enhancement of inflammation, anemia and reduced blood clotting (405).

Indeed, some researchers believe that more features of the etiology, pathogenesis, and pathophysiology of ischemic heart disease can be explained in terms of copper deficiency than can be explained by any other environmental insult (406). It is interesting to note therefore that

people with ischemic heart disease have been shown to have decreased cardiac and leucocyte copper and decreased activities of some copper-dependent enzymes (407).

Chromium

Infants	
0-6 mo	15µg
7-12 mo	30µg
Children	
1-3 y	40µg
4-8 y	65µg
Males	
9-13 y	115µg
14-18 y	190µg
19-30 y	200µg
31-50 y	200µg
50-70 y	200µg
> 70 y	200µg
Females	
9-13 y	115µg
14-18 y	190µg
19-30 y	200µg
31-50 y	200µg
50-70 y	200µg
> 70 y	200µg
Pregnancy	
≤ 18 y	210µg
19-30y	210µg
31-50 y	210µg
Lactation	
≤ 18 y	215µg
19-30y	215µg
31-50 y	215µg

Justification: Normal dietary intake of chromium for humans is suboptimal, and most diets contain less than 60% of the minimum suggested intake of 50µg (409).

Suboptimal dietary intake of chromium is associated with an increase in risk factors associated with diabetes and cardiovascular diseases (410), and produces signs and symptoms similar to those seen in these diseases (411).

Supplemental chromium is associated with a reduction in the risk factors for maturity-onset diabetes and cardiovascular diseases (412). Supplemental chromium given to people with impaired glucose tolerance or diabetes leads to improved blood glucose, insulin, and lipid variables (409).

Diabetics are frequently found to be low in chromium (413). Research has also demonstrated that plasma chromium levels are significantly lower in patients with coronary artery disease (423), and rheumatoid arthritis (424).

A daily supplement containing 200µg has been shown in some patients to be capable of reducing their requirements for insulin, sulfonylurea or metformin (414). Other research similarly confirms the beneficial effects of chromium supplements in individuals with diabetes (415-418). However, it is important to note that the beneficial effects of chromium in individuals with diabetes are generally only observed at levels higher than the upper limit of the Estimated Safe and Adequate Daily Dietary Intake (419). 200µg per day of supplemental chromium is adequate to improve glucose variables of those who are mildly glucose intolerant, whereas people with more overt impairments in glucose tolerance and diabetes usually require more than 200µg per day (420).

Chromium supplementation of normal adult men, as well as diabetics, has been reported to increase high density lipoprotein cholesterol and decrease triglycerides and total cholesterol (421). Indeed, some researchers consider that the beneficial effects of chromium repletion are now so well established and the trivalent form is so free of toxicity that it should now be used in clinical medicine for the benefit of those with some forms of diabetes and its complications and those suffering from atherosclerosis (422).

Chromium has also been shown to have antidepressant effects in patients with atypical depression (425), and has been found to be capable of increasing lean body mass in obese patients (426). Niacin-bound chromium supplements at a daily dose of 600µg have been demonstrated to cause overweight women on a modest dietary and exercise regimen to lose a significant amount of fat compared to placebo (427).

Finally, most recent evidence strongly supports the conclusion that there is little fear of toxic reactions from chromium consumption, and that supplementation may be useful to ameliorate many of the manifestations of ageing (411). In this respect, we note that the 350-fold difference between the acceptable daily intake and the calculated reference dose for humans of 70µg per day seems without precedent with respect to other nutritional minerals, and that the beneficial effects of chromium on serum glucose and lipids and insulin resistance occur even in the healthy (428).

Iodine

Infants	
0-6 mo	110µg
7-12 mo	130µg
Children	
1-3 y	90µg
4-8 y	90µg
Males	
9-13 y	120µg
14-18 y	150µg
19-30 y	150µg
31-50 y	150µg
50-70 y	150µg
> 70 y	150µg
Females	
9-13 y	120µg
14-18 y	150µg
19-30 y	150µg
31-50 y	150µg

50-70 y	150µg
> 70 y	150µg
Pregnancy	
≤ 18 y	220µg
19-30y	220µg
31-50 y	220µg
Lactation	
≤ 18 y	290µg
19-30y	290µg
31-50 y	290µg

Justification: The above figures are the current US NRVs for iodine (429), and the FAO/WHO Helsinki Consultation similarly set a figure of 150µg for Iodine when it met in 1988. We currently see no reason to alter these figures.

Iron

Infants	
0-6 mo	0.27mg
7-12 mo	11mg
Children	
1-3 y	7mg
4-8 y	10mg
Males	
9-13 y	8mg
14-18 y	11mg
19-30 y	8mg
31-50 y	8mg
50-70 y	8mg
> 70 y	8mg
Females	
9-13 y	8mg
14-18 y	15mg
19-30 y	18mg
31-50 y	18mg
50-70 y	8mg
> 70 y	8mg
Pregnancy	
≤ 18 y	27mg
19-30y	27mg
31-50 y	27mg
Lactation	
≤ 18 y	10mg
19-30y	9mg
31-50 y	9mg

Justification: The above figures are the current US NRVs for iron (430), and we broadly concur with the US supporting data.

Magnesium

Infants	
0-6 mo	40mg
7-12 mo	75mg
Children	
1-3 y	95mg
4-8 y	160mg
Males	
9-13 y	290mg
14-18 y	480mg
19-30 y	500mg
31-50 y	500mg
50-70 y	500mg
> 70 y	500mg
Females	
9-13 y	290mg
14-18 y	480mg
19-30 y	500mg
31-50 y	500mg
50-70 y	500mg
> 70 y	500mg
Pregnancy	
≤ 18 y	500mg
19-30y	520mg
31-50 y	520mg
Lactation	
≤ 18 y	520mg
19-30y	540mg
31-50 y	540mg

Justification: Research shows that dietary magnesium consumption has progressively declined over the past century from an average intake of 475-500mg in the period 1900-1908 to an average intake of 175-225mg in the period 1990-2002 (431).

As such it is hardly surprising that suboptimal intakes of magnesium and outright magnesium deficiencies are now commonplace in many population groups (435-452). Indeed, a large segment of the U.S. population may have a chronic latent magnesium deficiency that has been linked to atherosclerosis, myocardial infarction, hypertension, cancer, kidney stones, premenstrual syndrome, and psychiatric disorders (453). In this respect it should be noted that although serum levels are commonly used to assess magnesium deficiency, red cells and leucocytes can be still deficient despite normal serum values (454).

Magnesium deficiency produces abnormal cardiac rhythms that can cause sudden death from a heart attack (432, 433), and optimal levels of magnesium are strongly related to a lower risk of heart disease (434). Moreover, magnesium deficiency is commonplace in patients suffering from congestive heart failure (438), and a correlation between low magnesium consumption and the prevalence of the ischemic heart disease has been observed (451, 449). Further supporting evidence for the role of magnesium in protecting the heart can be drawn from the fact that magnesium infusions in patients with acute myocardial infarction have been shown to reduce the incidences of arrhythmias, death and the size of infarction (444).

In addition, serum magnesium levels are also known to be inversely associated with the risk of hypertension (448), and research has demonstrated that hypomagnesemia detected at the time of admission to hospital of acutely ill medical patients is associated with an increased mortality rate for both ward and intensive care unit patients (455).

Erythrocyte magnesium levels in patients with premenstrual tension syndrome have been shown to be significantly lower than those of the normal population (456), and as such it is believed that magnesium deficiency may also play a role in the etiology of this syndrome (457). Similarly, the biochemical signs of chronic magnesium deficiency are also known to be present in patients suffering from osteoporosis (459-461) and diabetes (462, 463).

Finally, we note that a 100 mg/day higher magnesium intake has been shown to be associated with better lung function and a reduced risk of airway hyper-reactivity and wheezing (458), and that a number of age-related neurodegenerative diseases have also been linked with various types of magnesium depletion (446).

Given that the World Health Organization currently attributes one-third of all global deaths annually (15.3 million) to cardiovascular disease (332) we have no hesitation in recommending the above NRVs for magnesium.

Manganese

Infants	
0-6 mo	0.4mg
7-12 mo	0.9mg
Children	
1-3 y	1.2mg
4-8 y	1.9mg
Males	
9-13 y	3.5mg
14-18 y	5.6mg
19-30 y	6.0mg
31-50 y	6.0mg
50-70 y	6.0mg
> 70 y	6.0mg
Females	
9-13 y	2.9mg
14-18 y	4.7mg
19-30 y	5.0mg
31-50 y	5.0mg
50-70 y	5.0mg
> 70 y	5.0mg
Pregnancy	
≤ 18 y	4.9mg
19-30y	5.2mg
31-50 y	5.2mg
Lactation	
≤ 18 y	5.1mg
19-30y	5.4mg

31-50 y 5.4mg

Justification: Patients suffering from osteoporosis have been found to have low blood levels of manganese (472, 473), and studies suggest that manganese supplements, either alone or in combination with other minerals, may both prevent fractures and halt bone loss (474, 475).

People with diabetes may also have low blood levels of manganese (476), and research suggests that manganese deficiency can contribute to glucose intolerance and that this may be reversed by supplementation (477).

Similarly, manganese deficiency may also aggravate Meniere's disease (481).

Research has also demonstrated that manganese supplements can both prevent and reverse the development of Tardive Dyskinesia (478-480).

Manganese is often low in refined and processed foods (482, 483). As such therefore, people whose diets consist primarily of these types of foods may consequently have a low manganese intake.

Finally, an increased manganese intake may be especially important whenever iron is supplemented, because iron can reduce the absorption of manganese and cause lower body levels of it (484).

Molybdenum

Infants	
0-6 mo	10µg
7-12 mo	20µg
Children	
1-3 y	30µg
4-8 y	50µg
Males	
9-13 y	90µg
14-18 y	140µg
19-30 y	150µg
31-50 y	150µg
50-70 y	150µg
> 70 y	150µg
Females	
9-13 y	70µg
14-18 y	100µg
19-30 y	125µg
31-50 y	125µg
50-70 y	125µg
> 70 y	125µg
Pregnancy	
≤ 18 y	105µg
19-30y	130µg
31-50 y	130µg
Lactation	

≤ 18 y	110µg
19-30y	135µg
31-50 y	135µg

Justification: The average diet in Western countries contains up to 500µg of molybdenum daily (485, 486).

Molybdenum levels in soil have been shown to be substantially lower in areas with the highest incidence of esophageal cancer (486, 487), and research suggests that molybdenum deficiency is associated with oesophageal cancer (486, 488).

Moreover, molybdenum also has an inhibitory effect upon gastrointestinal carcinogenesis, and research has demonstrated inverse correlations between molybdenum levels and female mortality from cancers of the esophagus and rectum (489).

Asthma symptoms are known to be triggered in some people by ingestion of sulfites, and molybdenum has been shown to aid in the detoxification of sulfites (490).

Trials have used molybdenum supplements in amounts of 500µg per day in the treatment of such conditions (491).

Molybdenum has also been shown to be useful in the treatment of children whose teeth have become stained through the ingestion of fluorine (492).

Finally, we note that molybdenum is accepted as an essential element and that it has a relatively low toxicity (485).

Selenium

Infants	
0-6 mo	15µg
7-12 mo	30µg
Children	
1-3 y	40µg
4-8 y	65µg
Males	
9-13 y	115µg
14-18 y	190µg
19-30 y	200µg
31-50 y	200µg
50-70 y	200µg
> 70 y	200µg
Females	
9-13 y	115µg
14-18 y	190µg
19-30 y	200µg
31-50 y	200µg
50-70 y	200µg
> 70 y	200µg
Pregnancy	
≤ 18 y	210µg
19-30y	210µg

31-50 y	210µg
Lactation	
≤ 18 y	215µg
19-30y	215µg
31-50 y	215µg

Justification: Selenium intake has been shown to be inadequate in many countries, and selenium deficiency is now relatively commonplace (493-501).

Research has demonstrated an inverse relationship between serum selenium levels and the incidence of cancer (502), and mounting evidence reveals that selenium has both anticarcinogenic and antitumorigenic properties (503).

Studies have also shown that the lower the soil levels of selenium are in a region the higher will be the prevalence of cancer in that region (504-506). In this respect it is interesting to note that researchers have measured the selenium content of the soil across the whole of the United States and found that it varies widely; the highest levels being found in the soil of South Dakota, and the lowest levels being found in Ohio. Analysis of this research showed that Rapid City, South Dakota, had the lowest overall cancer mortality rate in the whole of the United States, whilst the death rate from cancer in Ohio was almost twice that of South Dakota (507-510). Additional research has confirmed these results and extended them to almost thirty countries; definitively showing that the lower the intake of selenium the higher was the incidence of leukaemia and cancers of the large intestine, rectum, prostate, breast, ovary, lung, pancreas, skin and bladder (511). As such, the mythical “healthy diet” is clearly insufficient to prevent the development of cancer in areas where selenium is deficient in the soil.

Selenium supplements have been shown to reduce both the incidence of cancer and mortality resulting from it (512-516). Research has clearly shown, for example, that 200µg of supplemental selenium a day can reduce overall cancer mortality by 50% in humans compared to a placebo group not receiving supplemental selenium (517).

Research has also demonstrated an inverse relationship between serum selenium levels and the incidence of cardiovascular disease (502). Similarly, there is a significant, inverse correlation between plasma levels of selenium and severity of coronary atherosclerosis (518), and the serum selenium concentration of patients with acute myocardial infarction has been shown to be significantly lower than that of healthy people (519, 520). Indeed, low serum levels of selenium are associated with an increased risk of death from acute coronary heart disease and a higher risk of both fatal and nonfatal myocardial infarction (521). These findings are corroborated by separate research which shows a lower life expectancy and an elevated mortality from endemic and chronic diseases for people living in areas where the soil is deficient in selenium (534).

It has also been demonstrated that in the United States there is an inverse relationship between the quantity of selenium in the soil and mortality from AIDS (522). In this respect it is interesting to note that a selenium supplement of 200µg has been shown to markedly decrease the hospital admission rates of patients infected with HIV, decreasing the cost for hospitalization by 58% (523).

Patients with systemic inflammatory response syndrome (SIRS) have been found to have low selenium levels (524), as have patients suffering from chronic pancreatitis (525), and muscular dystrophy (526). Research also suggests that the incidence of goiter is related to low serum levels of selenium (529).

Selenium supplements have been found to improve immune function in corticoid-dependent asthmatics (527), and in patients on haemodialysis (528). When taken with supplements of vitamin E, selenium supplements, have also been shown to produce an improvement of sperm motility and semen quality (530, 531).

Finally, it has been shown that the lower the level of selenium in the diet the more subjects report feelings of anxiety, depression, and tiredness. A 100µg supplement of selenium however has been shown to elevate mood and in particular, decrease anxiety (532, 533).

Zinc

Infants	
0-6 mo	2mg
7-12 mo	4mg
Children	
1-3 y	6mg
4-8 y	10mg
Males	
9-13 y	17mg
14-18 y	28mg
19-30 y	30mg
31-50 y	30mg
50-70 y	30mg
> 70 y	30mg
Females	
9-13 y	14mg
14-18 y	23mg
19-30 y	25mg
31-50 y	25mg
50-70 y	25mg
> 70 y	25mg
Pregnancy	
≤ 18 y	24mg
19-30y	26mg
31-50 y	26mg
Lactation	
≤ 18 y	25mg
19-30y	27mg
31-50 y	27mg

Justification: An insufficient intake of zinc and/or zinc deficiency has been shown to be relatively common (393-395, 535-540), and a high serum copper concentration in the presence of low serum zinc is known to be associated with an increased mortality from all cardiovascular diseases and from coronary heart disease in particular (548).

Similarly, children who suffer from allergies are at risk of zinc deficiency (553), and patients suffering from Parkinson' s disease have been found to be functionally deficient in this nutrient (550).

Levels of zinc have also been shown to be significantly reduced in type-2 diabetes mellitus (541) and it has been established that zinc supplementation is helpful in achieving better glycemic control and improvement in the severity of peripheral neuropathy in diabetic patients (542).

Researchers have also demonstrated inverse correlations between blood pressure and serum levels of zinc (545), and that inadequate intakes of zinc are associated with an increased risk of bone fractures in middle-aged and elderly men (549).

Serum levels of zinc are frequently diminished in human immunodeficiency virus (HIV) infection, (543, 544), and research has shown that low levels of plasma zinc predict a 3-fold increase in HIV-related mortality, whereas normalization has been associated with significantly slower disease progression and a decrease in the rate of opportunistic infections (544).

It has also been shown that in patients with chronic liver disease the hepatic zinc concentration decreases as the severity of liver damage increases. Researchers have therefore suggested that zinc supplementation may improve hepatic encephalopathy by increasing the efficiency of the urea cycle (546). Indeed, zinc supplementation has also been found to improve glucose disposal in patients with cirrhosis (547).

Zinc supplements can have beneficial effects on the immune response in elderly people (556), and can decrease the incidence of infection and increase the survival rate following infection (557). Similarly, treatment of the common cold with zinc gluconate lozenges has been shown to result in a significant reduction in duration of symptoms (560).

In patients suffering from macular degeneration zinc supplements can reduce the visual loss associated with this disease (558).

Research also suggests that zinc inhibits human prostatic carcinoma cell growth (559).

People suffering from tinnitus have been shown to have lower levels of zinc than people who do not have tinnitus, and zinc supplements are known to be effective in decreasing the severity of this condition (551, 552).

Finally, we note that boys suffering from acne have been shown to have significantly lower serum levels of zinc than healthy subjects of the same age (554), and that researchers have demonstrated that zinc supplements are an effective treatment for this common adolescent condition (555).

REFERENCES

1. Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):713-20. Premenopausal intakes of vitamins A, C, and E, folate, and carotenoids, and risk of breast cancer. Cho E, Spiegelman D, Hunter DJ, Chen WY, Zhang SM, Colditz GA, Willett WC.
2. Br J Cancer. 2003 May 6;88(9):1381-7. Dietary intakes of vitamins A, C, and E and risk of melanoma in two cohorts of women. Feskanich D, Willett WC, Hunter DJ, Colditz GA.
3. J Biol Regul Homeost Agents. 2003 Jan-Mar;17(1):92-7. Retinoids in chemoprevention of cancer. Verma AK.

4. *Plant Foods Hum Nutr.* 2002 Fall;57(3-4):319-41.
Palm oil: biochemical, physiological, nutritional, hematological, and toxicological aspects: a review. Edem DO.
5. *Asian Pac J Cancer Prev.* 2001 Jul-Sep;2(3):215-224. A Study of Various Sociodemographic Factors and Plasma Vitamin Levels in Oral and Pharyngeal Cancer in Gujarat, India. Patel PS, Raval GN, Patel DD, Sainger RN, Shah MH, Shah JS, Patel MM, Dutta SJ, Patel BP.
6. *Cancer Sci.* 2003 Jan;94(1):57-63. Serum carotenoids and mortality from lung cancer: a case-control study nested in the Japan Collaborative Cohort (JACC) study. Ito Y, Wakai K, Suzuki K, Tamakoshi A, Seki N, Ando M, Nishino Y, Kondo T, Watanabe Y, Ozasa K, Ohno Y; JACC Study Group.
7. *Curr Drug Metab.* 2003 Feb;4(1):1-10. Retinoic acid metabolism and mechanism of action: a review. Marill J, Idres N, Capron CC, Nguyen E, Chabot GG.
8. *J Am Coll Nutr.* 1995 Oct;14(5):419-27. Epidemiologic studies of antioxidants and cancer in humans. Flagg EW, Coates RJ, Greenberg RS.
9. *Bibl Nutr Dieta.* 1995;(52):75-91. Cardiovascular disease and vitamins. Concurrent correction of ' suboptimal' plasma antioxidant levels may, as important part of 'optimal' nutrition, help to prevent early stages of cardiovascular disease and cancer, respectively. Gey KF.
10. *Cancer Causes Control.* 2001 Feb;12(2):163-72. Dietary patterns, nutrient intake and gastric cancer in a high-risk area of Italy. Palli D, Russo A, Decarli A.
11. *Soz Praventivmed.* 1989;34(2):75-7. Vitamins and cancer: results of a Basel study Stahelin HB.
12. *Am J Epidemiol.* 1991 Apr 15;133(8):766-75. Plasma antioxidant vitamins and subsequent cancer mortality in the 12-year follow-up of the prospective Basel Study. Stahelin HB, Gey KF, Eichholzer M, Ludin E, Bernasconi F, Thurneysen J, Brubacher G.
13. *Ital J Gastroenterol.* 1991 Sep-Oct;23(7):429-35. Gastric cancer in Italy. Cipriani F, Buiatti E, Palli D.
14. *EXS.* 1992;62:398-410. Inverse correlation between essential antioxidants in plasma and subsequent risk to develop cancer, ischemic heart disease and stroke respectively: 12-year follow-up of the Prospective Basel Study. Eichholzer M, Stahelin HB, Gey KF.
15. *Int J Cancer.* 1994 Mar 1;56(5):650-4. Serum micronutrients in relation to pre-cancerous gastric lesions. Zhang L, Blot WJ, You WC, Chang YS, Liu XQ, Kneller RW, Zhao L, Liu WD, Li JY, Jin ML, et al.
16. *Am J Epidemiol.* 1994 Mar 1;139(5):466-73. Nutritional factors and gastric cancer in Spain. Gonzalez CA, Riboli E, Badosa J, Batiste E, Cardona T, Pita S, Sanz JM, Torrent M, Agudo A.
17. *Int J Cancer.* 1994 Jun 1;57(5):638-44. Nutrients and gastric cancer risk. A population-based case-control study in Sweden. Hansson LE, Nyren O, Bergstrom R, Wolk A, Lindgren A, Baron J, Adami HO.

18. *Int J Cancer*. 1995 Mar 16;60(6):748-52. Attributable risks for stomach cancer in northern Italy. La Vecchia C, D'Avanzo B, Negri E, Decarli A, Benichou J.
19. *Zhonghua Yu Fang Yi Xue Za Zhi*. 1995 Jul;29(4):198-201. Relationship between serum micronutrients and precancerous gastric lesions Zhang L, Zhao L, Ma J.
20. *Int J Cancer*. 1996 Apr 10;66(2):145-50 Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Eichholzer M, Stahelin HB, Gey KF, Ludin E, Bernasconi F.
21. *Cancer Lett*. 1999 Feb 8;136(1):89-93
Serum antioxidative vitamin levels and lipid peroxidation in gastric carcinoma patients. Choi MA, Kim BS, Yu R.
22. *Int J Cancer*. 1998 Nov 9;78(4):415-20. Nutrient intake patterns and gastric cancer risk: a case-control study in Belgium. Kaaks R, Tuyns AJ, Haeltermann M, Riboli E.
23. *J Nutr*. 2002 Apr;132(4):756-61. A dietary oxidative balance score of vitamin C, beta-carotene and iron intakes and mortality risk in male smoking Belgians. Van Hoydonck PG, Temme EH, Schouten EG.
24. Mastroiacovo P, Mazzone T, Addis A, Elephant E, Carlier P, Vial T, Garbis H, Robert E, Bonati M, Ornoy A, Finardi A, Schaffer C, Caramelli L, Rodriguez-Pinilla E, Clementi M. High vitamin A intake in early pregnancy and major malformations: a multicenter prospective controlled study. *Teratology*. 1999 Jan;59(1):7-11.
25. Biesalski HK. Comparative assessment of the toxicology of vitamin A and retinoids in man. *Toxicology* 1989;57:117-61).
26. Wiegand UW, Hartmann S, Hummler H. Safety of vitamin A: recent results. *Int J Vitam Nutr Res* 1998;68:411-6 [review].
27. Lonsdale D. *The Nutritionist's Guide to the Clinical Use of Vitamin B-1*. Tacoma, WA: Life Sciences Press: 44-77.
28. Cheraskin E, Ringsdorf WM, Medford FH, Hicks BS. The "ideal" daily vitamin B1 intake. *J Oral Med* 1978;33:77-79.
29. *Am J Clin Nutr*, 2002, vol.75, 616-58, 377. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased K-m): relevance to genetic disease and polymorphisms. Ames BN et al.
30. Cheraskin E, Ringsdorf WM. How much carbohydrate should we eat? *Am Lab* 1974;6:31-35.
31. *Nutr Rev*. 2002 Sep;60(9):277-80. Acute versus marginal deficiencies of nutrients. Carpenter KJ. USA
32. *Neurochem Int*. 2002 May;40(6):493-504. Interactions of oxidative stress with thiamine homeostasis promote neurodegeneration. Gibson GE, Zhang H.

33. *Am J Ophthalmol.* 2001 Jul;132(1):19-26. Use of vitamin supplements and cataract: the Blue Mountains Eye Study. Kuzniarz M, Mitchell P, Cumming RG, Flood VM.
34. *Br J Nutr.* 2001 Jun;85(6):741-8. Vitamin B intake and status in healthy Havanan men, 2 years after the Cuban neuropathy epidemic. Arnaud J, Fleites-Mestre P, Chassagne M, Verdura T, Garcia Garcia I, Hernandez-Fernandez T, Gautier H, Favier A, Perez-Cristia R, Barnouin J.
35. *Behav Brain Res.* 2001 Mar 15;119(2):167-77. Aging potentiates the acute and chronic neurological symptoms of pyriethiamine-induced thiamine deficiency in the rodent. Pitkin SR, Savage LM.
36. *Nihon Arukoru Yakubutsu Igakkai Zasshi.* 2000 Feb;35(1):19-27. Alcohol intake and nutrition. Itokawa Y.
37. *Public Health Nutr.* 1999 Sep;2(3A):403-9. The effects of nutrients on mood. Benton D, Donohoe RT.
38. *Wei Sheng Yan Jiu.* 1997 Mar;26(2):122-5. Relationship between dietary nutrients intakes and human prostate cancer Du S, Shi L, Zhang H, He S.
39. *Psychopharmacology (Berl).* 1997 Jan;129(1):66-71. Thiamine supplementation mood and cognitive functioning. Benton D, Griffiths R, Haller J. UK
40. *Z Ernährungswiss.* 1996 Sep;35(3):266-72. Can megadoses of thiamine prevent ethanol-induced damages of rat hippocampal CA1 pyramidal neurones? Wenisch S, Steinmetz T, Fortmann B, Leiser R, Bitsch I.
41. *Metab Brain Dis.* 1996 Mar;11(1):95-106. Effects of thiamine supplementation on exercise-induced fatigue. Suzuki M, Itokawa Y. Japan
42. *J Neurochem.* 1996 Jan;66(1):250-8. Thiamine, thiamine phosphates, and their metabolizing enzymes in human brain. Bettendorff L, Mastrogiacomo F, Kish SJ, Grisar T.
43. *J Med Assoc Thai.* 1993 Oct;76 Suppl 2:138-45. Effects of multivitamin supplementation for improvement of thiamin, riboflavin, and retinol nutrition in pediatric patients. Angkatavanich J, Suthutvoravut U, Panijpan B, Tontisirin K.
44. *J Epidemiol Community Health.* 1991 Jun;45(2):148-51. Relation between diet composition and coronary heart disease risk factors. Porrini M, Simonetti P, Testolin G, Roggi C, Laddomada MS, Tenconi MT.
45. *Int J Cancer.* 1998 Nov 9;78(4):415-20. Nutrient intake patterns and gastric cancer risk: a case-control study in Belgium. Kaaks R, Tuyns AJ, Haeltersman M, Riboli E.
46. *Med Hypotheses.* 2000 Jul;55(1):88-90. Thiamine supplementation to prevent induction of low birth weight by conventional therapy for gestational diabetes mellitus. Bakker SJ, ter Maaten JC, Gans RO.
47. *Am J Clin Nutr.* 2000 Aug;72(2 Suppl):598S-606S. Effect of physical activity on thiamine, riboflavin, and vitamin B-6 requirements. Manore MM.

48. Age Ageing. 2000 Mar;29(2):111-6. Comment in: Age Ageing. 2000 Mar;29(2):99-101. Is thiamine deficiency in elderly people related to age or co-morbidity? Wilkinson TJ, Hanger HC, George PM, Sainsbury R.
49. Arch Neurol. 1995 Nov;52(11):1081-6. Plasma and red blood cell thiamine deficiency in patients with dementia of the Alzheimer's type. Gold M, Chen MF, Johnson K.
49. Gerontology. 1994;40(1):18-24. O' Keefe ST, Tormey WP, Glasgow R, Lavan JN.
50. J Nutr Health Aging. 2003;7(2):121-8. Assessment of antioxidant nutrient intake of a population of southern U.S. African-american and caucasian women of various ages when compared to dietary reference intakes. Lewis SM, Mayhugh MA, Freni SC, Thorn B, Cardoso S, Buffington C, Jairaj K, Feuers RJ.
51. Pol Merkuriusz Lek. 2002 Dec;13(78):490-6. Dietary intake elderly subjects in rural and urban area in Poland, Rychlik E.
52. Eur J Clin Nutr. 2002 Nov;56(11):1119-25. Diet and nutritional status of rural adolescents in India. Venkaiah K, Damayanti K, Nayak MU, Vijayaraghavan K.
53. J Med Assoc Thai. 1993 Oct;76 Suppl 2:138-45. Effects of multivitamin supplementation for improvement of thiamin, riboflavin, and retinol nutrition in pediatric patients. Angkatavanich J, Suthutvoravut U, Panijpan B, Tontisirin K.
54. Vopr Pitan. 2001;70(1):12-4. Effects of biologically active supplements on the antioxidant and vitamin status of patients with hypertension and ischemic heart disease. Tutel'ian VA, Pogozheva AV, Rumiantseva OI, Akol'zina SE, Lysikova SL, Kodentsova VM, Mal'tsev Glu.
55. J Am Diet Assoc. 1995 Dec;95(12):1409-13. High-risk nutrient intakes among low-income Mexican women in Chicago, Illinois. Ballew C, Sugerman SB.
56. Biochem Biophys Res Commun. 1995 Jul 6;212(1):35-40. Myocardial flavin reductase and riboflavin: a potential role in decreasing reoxygenation injury. Mack CP, Hultquist DE, Schlafer M.
57. J Am Coll Nutr. 1995 Feb;14(1):71-9. The important role of modifiable dietary and behavioral characteristics in the causation and prevention of coronary heart disease hospitalization and mortality: the prospective NHANES I follow-up study. Gartside PS, Glueck CJ.
58. Nutr Rev. 1993 May;51(5):149-50. Riboflavin can protect tissue from oxidative injury. Christensen HN.
59. J Epidemiol Community Health. 1991 Jun;45(2):148-51. Relation between diet composition and coronary heart disease risk factors. Porrini M, Simonetti P, Testolin G, Roggi C, Laddomada MS, Tenconi MT.
60. Atherosclerosis. 1989 Jan;75(1):1-6. Reduction of plasma lipid and homocysteine levels by pyridoxine, folate, cobalamin, choline, riboflavin, and troxerutin in atherosclerosis. Olszewski AJ, Szostak WB, Bialkowska M, Rudnicki S, McCully KS.
61. Ann Rheum Dis. 1996 Nov;55(11):837-40. Glutathione reductase activity, riboflavin status, and disease activity in rheumatoid arthritis. Mulherin DM, Thurnham DI, Situnayake RD.

62. *Int J Epidemiol.* 1998 Oct;27(5):845-52. Nutritional factors in the aetiology of multiple sclerosis: a case-control study in Montreal, Canada. Ghadirian P, Jain M, Ducic S, Shatenstein B, Morisset R.
63. *Epilepsy Res.* 2002 Oct;51(3):237-47. The effect of B-vitamins on hyperhomocysteinemia in patients on antiepileptic drugs. Apeland T, Mansoor MA, Pentieva K, McNulty H, Seljeflot I, Strandjord RE.
64. *Eur J Clin Nutr.* 1988 Apr;42(4):277-83. Riboflavin deficiency and severity of malaria. Das BS, Das DB, Satpathy RN, Patnaik JK, Bose TK.
65. Food consumption and dietary adequacy according to income in 1,200 families, Manaus, Amazonas, Brazil, 1973-1974. Shrimpton R.
66. *Hum Nutr Clin Nutr.* 1983 Dec;37(6):427-32. Efficacy of a riboflavin supplement given at fortnightly intervals to pregnant and lactating women in rural Gambia. Bates CJ, Flewitt A, Prentice AM, Lamb WH, Whitehead RG.
67. *Am J Clin Nutr.* 2003 Jun;77(6):1352-60. Riboflavin (vitamin B-2) and health. Powers HJ.
68. *Arch Ophthalmol.* 2001 Jul;119(7):1009-19. Long-term nutrient intake and early age-related nuclear lens opacities. Jacques PF, Chylack LT Jr, Hankinson SE, Khu PM, Rogers G, Friend J, Tung W, Wolfe JK, Padhye N, Willett WC, Taylor A.
69. *Neuropsychobiology.* 1995;32(2):98-105. Vitamin supplementation for 1 year improves mood. Benton D, Haller J, Fordy J.
70. Canner PL et al. Fifteen year mortality in coronary drug project patients: Long term benefit with niacin. *Journal of the American College of Cardiology.* 8:1245-1255, 1986.
71. Velling DA, Dodick DW, Muir JJ. Sustained-release niacin for prevention of migraine headache. *Mayo Clin Proc.* 2003 Jun;78(6):770-1.
72. Negri E, Franceschi S, Bosetti C, et al. Selected micronutrients and oral and pharyngeal cancer. *Int J Cancer.* 2000;86(1):122-127.
73. Franceschi S, Bidoli E, Negri E, et al. Role of macronutrients, vitamins and minerals in the aetiology of squamous-cell carcinoma of the oesophagus. *Int J Cancer.* 2000;86(5):626-631.
74. Hawkins D. Orthomolecular psychiatry: Treatment of schizophrenia. In: Hawkins D and Pauling L (eds.). *Orthomolecular psychiatry.* San Francisco: WH Freeman and Company, pp. 667-668, 1973.
75. Hawkins DR, Bortin AW, Runyon RP. Orthomolecular psychiatry: niacin and megavitamin therapy. *Psychosomatics.* Sep-Oct;11(5):517-21. 1970.
76. Hoffer, A., Osmond, H., Callbeck, J.M., and Kahan, I. (1957) Treatment of schizophrenia with nicotinic acid and nicotinamide. *Journal of Clinical Experimental Psychopathology* 18:131-158.
77. Hoffer, Abram (1962) *Niacin Therapy in Psychiatry.* Springfield, IL: Charles S. Thomas.

78. Hoffer, Abram and Osmond, Humphrey Treatment of schizophrenia with nicotinic acid: a ten-year follow-up. *Acta Psychiatr Scand* 40:171-189, 1964.
79. Hoffer, Abram. Use of ascorbic acid with niacin in schizophrenia. *Canadian Medical Journal*, November 6, 1971.
80. Osmond, Humphrey and Hoffer, Abram (1962) Massive niacin treatment in schizophrenia: review of a nine-year study. *Lancet* 1:316-319.
81. Hoffer A. Treatment of arthritis by nicotinic acid and nicotinamide. *Can. Med. Assoc. J.* 81:235, 1959.
82. Kaufman W. Niacinamide therapy for joint mobility: Therapeutic reversal of a common clinical manifestation of the 'normal' ageing process. *Conn. St. Med. J.* 81:235, 1959.
83. Vogue P et al. Nicotinamide may extend remission phase in insulin-dependent diabetes. *Lancet.* 1:619, 1987.
84. Shansky. Vitamin B3 in the alleviation of Hypoglycemia. *Drug and Cosmetic Industry.* Oct. 1981.
85. Carlson LA, Hamsten A and Asplund A. Pronounced lowering of serum levels of lipoprotein Lp (a) in hyperlipidemic subjects treated with nicotinic acid. *Journal of Internal Medicine.* 226:271-276, 1989.
86. Luria MH. Effect of low-dose niacin on high density lipoprotein cholesterol and total cholesterol/high density lipoprotein cholesterol ratio. *Archives of Internal Medicine.* 148:2493-2495, 1988.
87. Yovos JG et al. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia. *Journal of Clinical Endocrinology and Metabolism.* 54:1210-1215, 1982.
88. Charman et al. Nicotinic acid in the treatment of hypercholesterolemia. *J. Angiology.* Jan. 1973.
89. The effect of Nicotinic Acid on the Plasma Free Fatty Acids. *Acta Medica Scandinavica* 172 fasc. 6, 1962.
90. Miettinen et al. *Acta Med. Scand.* 186:247-253, 1969.
91. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. *Archives of Biochemistry and Biophysics.* 54:558-559, 1955.
92. Guraker A, Hoeg JM, Kostner G, Papadopoulos NM, Brewer HB Jr. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. *Atherosclerosis.* 57:293-301, 1985.
93. Lavie CJ. Marked benefit with sustained-release niacin therapy in patients with isolated very low levels of high-density lipoprotein cholesterol and coronary artery disease. *The American Journal of Cardiology.* 69:1083-1085, 1992.

94. Barton-Wright EC and Elliott WA. The pantothenic acid metabolism of rheumatoid arthritis. *Lancet*. 2:862-863, 1963.
95. General Practitioner Research Group. Calcium pantothenate in arthritic conditions. *Practitioner*. 224:208-211, 1980.
96. Gaddi A, Descovich GC, Nosedà G, et al. Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia. *Atherosclerosis*. 1984;50(1):73-83.
97. Coronel F, Tornero F, Torrente J, et al. Treatment of hyperlipemia in diabetic patients on dialysis with a physiological substance. *Am J Nephrol*. 1991;11(1):32-36.
98. Avogaro P, Bon GB, Fusello M. Effect of pantethine on lipids, lipoproteins and apolipoproteins in man. *Current Therapeutic Research*. 33:488-493, 1983.
99. Galeone F, Scalabrino A, Giuntoli F, Birindelli A, Panigada G, Rossi, Saba P. The lipid-lowering effect of pantethine in hyperlipidemic patients: A clinical investigation. *Current Therapeutic Research*. 34:383-390, 1983.
100. Miccoli R, Marchetti P, Sampietro T, Benzi L, Tognarelli M, Navalesi R. Effects of pantethine on lipids and apolipoproteins in hypocholesterolemic diabetic and non-diabetic patients. *Current Therapeutic Research*. 36:545-549, 1984.
101. Litoff D, Scherzer H, Harrison J. Effects of pantothenic acid supplementation on human exercise. *Med Sci Sports Exercise*. 1985; 17:287(Abstract 17).
102. Moiseenok, A.G., Komar, V.I., Khomich, T.I. et al. Pantothenic acid in maintaining thiol and immune homeostasis. *Biofactors*, 11:53-55, 2000.
103. Department of Health Report on Health and Social Subjects 16: Nutrition and Health in Old Age. London, HMSO, 1979.
104. Fries M.E., Chrisley B.M., Driskell J.A., Vitamin B6 status of a group of preschool children. *Am J Clin Nutr* 1981; 34: 2806-2810.
105. Schuster K., Bailey L.B., Mahan C.A., Vitamin B6 status of low-income adolescent and adult pregnant women and the condition of their infants at birth. *Am J Clin Nutr* 1981; 34: 1731-1735.
106. Bender D.A., Vitamin B6 requirements and recommendations. *Eur J Clin Nutr* 1989; 43: 289-309.
107. Talbott MC, Miller LT, Kerkvliet NI. Pyridoxine supplementation: Effect on lymphocyte responses in elderly persons. *Am. J. Clin. Nutr.* 46:659, 1987.
108. Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Intake of vitamins B6 and C and the risk of kidney stones in women. *J Am Soc Nephrol*. 1999;10(4):840-845.
109. Abraham GE, Hargrove J. Effect of vitamin B6 on pre-menstrual symptomatology in women with pre-menstrual syndromes: A double-blind cross-over study. *Infertility*. 3:155-165, 1980.

110. Webb JL. Nutritional Effects of Oral Contraceptive Use: A Review. *J. Reprod Med*, 1980. 25 (4):150-6.
111. Prasad AS, Lei KY, Moghissi KS, et al. Effect of Oral Contraceptives on Nutrients. III. Vitamins B6, B12, and Folic Acid. *Am J Obstet Gynecol*, 1976, 125(8):1063-9.
112. Ahmed F, Bamji MS, Iyengar L. Effect of Oral Contraceptive Agents on Vitamin Nutrition Status. *Am J Clin Nutr*. 1975, 28(6):606-15.
113. Bhagavan HN, Brin M. Drug-Vitamin B6 Interaction. *Curr Concepts Nutr*. 1983, 12:1-12.
114. Haspels AA, Bennink HJ, Schreurs WH. Disturbance of Tryptophan Metabolism and Its Correction During Oestrogen Treatment in Postmenopausal Women. *Maturitas*. 1978, 1(1):15-20.
115. Bermond P. Therapy of Side Effects of Oral Contraceptive Agents With Vitamin B6. *Acta Vitaminal Enzymol*. 1982, 4(1-2):45-54.
116. Kishi H, Kishi T, Williams RH, et al. Deficiency of Vitamin B6 in Women Taking Contraceptive Formulations. *Res Commun Chem Pathol Pharamcol*. 1997, 17(2):283-93.
117. Baumblatt MJ, Winston F. Pyridoxine and the pill. *Lancet* 1970 Apr 18;1(7651):832-833.
118. Rimland B, Callaway E, Dreyfus P. The effect of high doses of vitamin B6 on autistic children: a double-blind crossover study. *Am J Psychiatry*. 1978 Apr;135(4):472-5.
119. Collipp PJ et al, Pyridoxine treatment of childhood bronchial asthma. *Ann Allergy* 1975; 35: 93-7.
120. Natta CL et al, Apparent Vitamin B6 deficiency in sickle cell anaemia. *Am J Clin Nutr* 1984; 40: 235-9.
121. Vutyavanich T, Wongtra-ngan S, Ruangsri R. Pyridoxine for nausea and vomiting of pregnancy: a randomized, double-blind, placebo-controlled trial. *Am J Obstet Gynecol*. 1995;173 (3 Pt 1):881-884.
122. Sahakian V, Rouse D, Sipes S, Rose N, Niebyl J. Vitamin B6 is effective therapy for nausea and vomiting of pregnancy: a randomized, double-blind placebo-controlled study. *Obstet Gynecol*. 1991;78(1):33-36.
123. Folkers K, Ellis J, Watanabe T, Saji S, Kaji M. Biochemical evidence for a deficiency of vitamin B6 in the carpal tunnel syndrome based on a crossover clinical study. *Proc Natl Acad Sci U S A*. 1978 Jul;75(7):3410-2.
124. Ellis JM. Treatment of carpal tunnel syndrome with vitamin B6. *Southern Medical Journal*. 80:882-884, 1987.
125. Ellis JM et al. Response of vitamin B6 deficiency and the carpal tunnel syndrome to pyridoxine. *Proc Natl Acad Sci USA* 79 (1982), 7494-8.

126. Krishnaswamy K, Lakshmi AV. Role of nutritional supplementation in reducing the levels of homocysteine. *J Assoc Physicians India*. 2002 May;50 Suppl:36-42.
127. Leowattana W, Mahanonda N, Bhuripunyo K, Pokum S. Association between serum homocysteine, vitamin B12, folate and Thai coronary artery disease patients. *J Med Assoc Thai*. 2000 May;83(5):536-42.
128. Temple ME, Luzier AB, Kazierad DJ. Homocysteine as a risk factor for atherosclerosis. *Ann Pharmacother*. 2000 Jan;34(1):57-65.
129. Lewerin C, Nilsson-Ehle H, Matousek M, Lindstedt G, Steen B. Reduction of plasma homocysteine and serum methylmalonate concentrations in apparently healthy elderly subjects after treatment with folic acid, vitamin B12 and vitamin B6: a randomised trial. *Eur J Clin Nutr*. 2003 Nov;57(11):1426-36.
130. J. Selhub, P.F. Jacques, P.W. Wilson, D. Rush, I.H. Rosenberg. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. *JAMA*, 1993, Dec 8: 2693-2698.
131. Hartman TJ, Woodson K, Stolzenberg-Solomon R, Virtamo J, Selhub J, Barrett MJ, Albanes D. Association of the B-vitamins pyridoxal 5' -phosphate (B(6)), B(12), and folate with lung cancer risk in older men. *Am J Epidemiol*. 2001 Apr 1;153(7):688-94.
132. Vutyavanich T, Wongtra-ngan S, Ruangsri R. Pyridoxine for nausea and vomiting of pregnancy: a randomized, double-blind, placebo-controlled trial. *Am J Obstet Gynecol*. 1995;173 (3 Pt 1):881-884.
133. Doyle W., Crawford M.A., Wynn A.H.A., Wynn S.W., The Association between Maternal Diet and Birth Dimensions. *J Nutr Med* 1990; 1: 9-17.
134. Goutieres F, Aicardi J. Atypical presentations of pyridoxine dependent seizures: a treatable cause of intractable epilepsy in infants. *Annals of Neurology*. 17:117-120, 1985.
135. Reiter LA, Boylan LM, Driskell J, Moak S. Vitamin B-12 and folate intakes and plasma levels of black adolescent females. *J Am Diet Assoc*. 1987 Aug;87(8):1065-7.
136. Obeid R, Geisel J, Schorr H, Hubner U, Herrmann W. The impact of vegetarianism on some haematological parameters. *Eur J Haematol*. 2002 Nov-Dec;69(5-6):275-9.
137. Garcia-Arias MT, Villarino Rodriguez A, Garcia-Linares MC, Rocandio AM, Garcia-Fernandez MC. Iron, folate and vitamins B12 & C dietary intake of an elderly institutionalized population in Leon, Spain. *Nutr Hosp*. 2003 Jul-Aug;18(4):222-5.
138. Baik HW, Russell RM. Vitamin B12 deficiency in the elderly. *Annu Rev Nutr*. 1999;19:357-377.
139. Watts DT. Vitamin B12 replacement therapy: how much is enough? *Wis Med J*. 1994 May;93 (5):203-5.
140. McRae TD, Freedman ML. Why vitamin B12 deficiency should be managed aggressively. *Geriatrics*. 1989 Nov;44(11):70-3, 76, 79.

141. Wu K, Helzlsouer KJ, Comstock GW, Hoffman SC, Nadeau MR, Selhub J. A prospective study on folate, B12, and pyridoxal 5'-phosphate (B6) and breast cancer. *Cancer Epidemiol Biomarkers Prev.* 1999;8(3):209-217.
142. Wang HX, Wahlin A, Basun H, Fastbom J, Winblad B, Fratiglioni L. Vitamin B(12) and folate in relation to the development of Alzheimer's disease. *Neurology.* 2001;56(9):1188-1194.
143. Flynn MA, Irvin W, Krause G. The effect of folate and cobalamin on osteoarthritic hands. *J Am Coll Nutr.* 1994 Aug;13(4):351-6
144. Saito M, Kato H, Tsuchida T, Konaka C. Chemoprevention effects on bronchial squamous metaplasia by folate and vitamin B12 in heavy smokers. *Chest.* 1994 Aug;106(2):496-9.
145. Heimbürger DC, Alexander CB, Birch R, Butterworth CE Jr, Bailey WC, Krumdieck CL. Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12. Report of a preliminary randomized, double-blind intervention trial. *JAMA.* 1988 Mar 11;259(10):1525-30.
146. Seror P. Sciatica cured by vitamin B12. *Rev Rhum Mal Osteoartic.* 1989 Mar 15;56(4):344.
147. Ostreicher DS. Vitamin B12 supplements as protection against nitrous oxide inhalation. *N Y State Dent J.* 1994 Mar;60(3):47-9.
148. Korkina MB, Korchak GM, Medvedev DI. Clinico-experimental substantiation of the use of carnitine and cobalamin in the treatment of anorexia nervosa. *Zh Nevropatol Psikhiatr Im S S Korsakova.* 1989;89(2):82-7.
149. Kark JD, Sinnreich R, Rosenberg IH, Jacques PF, Selhub J. Plasma homocysteine and parental myocardial infarction in young adults in Jerusalem. *Circulation.* 2002 Jun 11;105(23):2725-9.
150. Zhang G, Dai C. Correlation analysis between plasma homocysteine level and polymorphism of homocysteine metabolism related enzymes in ischemic cerebrovascular or cardiovascular diseases. *Zhonghua Xue Ye Xue Za Zhi.* 2002 Mar;23(3):126-9.
151. Gao W, Jiang N, Zhu G. The mechanisms of hyperhomocysteinemia in coronary heart disease. *Zhonghua Yi Xue Za Zhi.* 1998 Nov;78(11):821-3.
152. Leowattana W, Mahanonda N, Bhuripunyo K, Pokum S. Association between serum homocysteine, vitamin B12, folate and Thai coronary artery disease patients. *J Med Assoc Thai.* 2000 May;83(5):536-42.
153. Adunsky A, Weitzman A, Fleissig Y, Levenkrohn L, Arad M, Doolman R, Gavendo S, Sela BA. The relation of plasma total homocysteine levels to prevalent cardiovascular disease in older patients with ischemic stroke. *Aging (Milano).* 2000 Feb;12(1):48-52.
154. Turgan N, Boydak B, Habif S, Apakkan S, Ozmen D, Mutaf I, Bayindir O. Plasma homocysteine levels in acute coronary syndromes. *Jpn Heart J.* 1999 Nov;40(6):729-36.

155. Giles WH, Croft JB, Greenlund KJ, Ford ES, Kittner SJ. Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: Results from the Third National Health and Nutrition Examination Survey. *Am Heart J.* 2000 Mar;139(3):446-53.
156. Temple ME, Luzier AB, Kazierad DJ. Homocysteine as a risk factor for atherosclerosis. *Ann Pharmacother.* 2000 Jan;34(1):57-65.
157. Fanapour PC, Yug B, Kochar MS. Hyperhomocysteinemia: an additional cardiovascular risk factor. *WMJ.* 1999 Dec;98(8):51-4.
158. Whincup PH, Refsum H, Perry IJ, Morris R, Walker M, Lennon L, Thomson A, Ueland PM, Ebrahim SB. Serum total homocysteine and coronary heart disease: prospective study in middle aged men. *Heart.* 1999 Oct;82(4):448-54.
159. Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JC, Koudstaal PJ, Grobbee DE. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. *Arch Intern Med.* 1999 Jan 11;159(1):38-44.
160. Stehouwer CD, Weijnenberg MP, van den Berg M, Jakobs C, Feskens EJ, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. *Arterioscler Thromb Vasc Biol.* 1998 Dec;18(12):1895-901.
161. Verhoef P, Kok FJ, Kruyssen DA, Schouten EG, Witteman JC, Grobbee DE, Ueland PM, Refsum H. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. *Arterioscler Thromb Vasc Biol.* 1997 May;17(5):989-95.
162. Krishnaswamy K, Lakshmi AV. Role of nutritional supplementation in reducing the levels of homocysteine. *J Assoc Physicians India.* 2002 May;50 Suppl:36-42.
163. J. Selhub, P.F. Jacques, P.W. Wilson, D. Rush, I.H. Rosenberg. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. *JAMA*, 1993, Dec 8: 2693-2698.
164. Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, Weger M. DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. *Clin Chem Lab Med.* 2003 Nov;41(11):1392-403.
165. Krishnaswamy K, Lakshmi AV. Role of nutritional supplementation in reducing the levels of homocysteine. *J Assoc Physicians India.* 2002 May;50 Suppl:36-42.
166. Leowattana W, Mahanonda N, Bhuripunyo K, Pokum S. Association between serum homocysteine, vitamin B12, folate and Thai coronary artery disease patients. *J Med Assoc Thai.* 2000 May;83(5):536-42.
167. Temple ME, Luzier AB, Kazierad DJ. Homocysteine as a risk factor for atherosclerosis. *Ann Pharmacother.* 2000 Jan;34(1):57-65.
168. Lewerin C, Nilsson-Ehle H, Matousek M, Lindstedt G, Steen B. Reduction of plasma homocysteine and serum methylmalonate concentrations in apparently healthy elderly subjects

after treatment with folic acid, vitamin B12 and vitamin B6: a randomised trial. *Eur J Clin Nutr.* 2003 Nov;57(11):1426-36.

169. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. *N Engl J Med.* 2002;346(7):476-483.

170. Hutto BR. Folate and cobalamin in psychiatric illness. *Compr Psychiatry.* 1997;38(6):305-314.

171. Penninx BW, Guralnik JM, Ferrucci L, Fried LP, Allen RH, Stabler SP. Vitamin B(12) deficiency and depression in physically disabled older women: epidemiologic evidence from the Women's Health and Aging Study. *Am J Psychiatry.* 2000;157(5):715-721.

172. Edwin E, Holten K, Norum KR, Schrupf A, Skaug OE. Vitamin B12 Hypovitaminosis in Mental Diseases. *Acta Medical Scandinavica.* 1965;177:689-699.

173. Bryan J, Calvaresi E, Hughes D. Short-term folate, vitamin B-12 or vitamin B-6 supplementation slightly affects memory performance but not mood in women of various ages. *J Nutr.* 2002 Jun;132(6):1345-56.

174. Newbold HL. Vitamin B-12: placebo or neglected therapeutic tool? *Med Hypotheses.* 1989 Mar;28(3):155-64.

175. La Rue A, Koehler KM, Wayne SJ, Chiulli SJ, Haaland KY, Garry PJ. Nutritional status and cognitive functioning in a normally aging sample: a 6-y reassessment. *Am J Clin Nutr.* 1997 Jan;65(1):20-9.

176. Rajan S, Wallace JI, Beresford SA, Brodtkin KI, Allen RA, Stabler SP. Screening for cobalamin deficiency in geriatric outpatients: prevalence and influence of synthetic cobalamin intake. *J Am Geriatr Soc.* 2002 Apr;50(4):624-30.

177. Bopp-Kistler I, Ruegger-Frey B, Grob D, Six P. Vitamin B12 deficiency in geriatrics. *Schweiz Rundsch Med Prax.* 1999 Nov 4;88(45):1867-75.

178. Gonzalez-Gross M, Prinz-Langenohl R, Pietrzik K. Folate status in Germany 1997-2000. *Int J Vitam Nutr Res.* 2002 Dec;72(6):351-9.

179. Hilton JJ. Folic acid intake of young women. *J Obstet Gynecol Neonatal Nurs.* 2002 Mar-Apr;31(2):172-7.

180. Konings EJ, Roomans HH, Dorant E, Goldbohm RA, Saris WH, van den Brandt PA. Folate intake of the Dutch population according to newly established liquid chromatography data for foods. *Am J Clin Nutr.* 2001 Apr;73(4):765-76.

181. Clarke R, Grimley Evans J, Schneede J, Nexo E, Bates C, Fletcher A, Prentice A, Johnston C, Ueland PM, Refsum H, Sherliker P, Birks J, Whitlock G, Breeze E, Scott JM. Vitamin B12 and folate deficiency in later life. *Age Ageing.* 2004 Jan;33(1):34-41.

182. Figlin E, Chetrit A, Shahar A, Shpilberg O, Zivelin A, Rosenberg N, Brok-Simoni F, Gadoth N, Sela BA, Seligsohn U. High prevalences of vitamin B12 and folic acid deficiency in elderly subjects in Israel. *Br J Haematol.* 2003 Nov;123(4):696-701.

183. Hultberg B, Nilsson K, Isaksson A, Gustafson L. Folate deficiency is a common finding in psychogeriatric patients. *Aging Clin Exp Res*. 2002 Dec;14(6):479-84.
184. Serra-Majem L, Ribas L, Ngo J, Aranceta J, Garaulet M, Carazo E, Mataix J, Perez-Rodrigo C, Quemada M, Tojo R, Vazquez C. Risk of inadequate intakes of vitamins A, B1, B6, C, E, folate, iron and calcium in the Spanish population aged 4 to 18.
185. *Int J Vitam Nutr Res*. 2001 Nov;71(6):325-31. Wright JD, Bialostosky K, Gunter EW, Carroll MD, Najjar MF, Bowman BA, Johnson CL. Blood folate and vitamin B12: United States, 1988-94. *Vital Health Stat 11*. 1998 Dec;(243):1-78.
186. Villarino Rodriguez A, Garcia-Linares Mdel C, Garcia-Arias MT, Garcia-Fernandez Mdel C. Anthropometric assessment and vitamin intake by a group of elderly institutionalized individuals in the province of Leon (Spain). *Nutr Hosp*. 2002 Nov-Dec;17(6):290-5.
187. Morris MS, Fava M, Jacques PF, Selhub J, Rosenberg IH. Depression and folate status in the US Population. *Psychother Psychosom*. 2003 Mar-Apr;72(2):80-7.
188. Fuchs I, Omansky L, Lerner Y. Folic acid deficiency in chronically hospitalized mental patients. *Harefuah*. 1998 Sep;135(5-6):186-7, 255.
189. Kelly GS. Folates: supplemental forms and therapeutic applications. *Altern Med Rev*. 1998 Jun;3(3):208-20.
190. Giovannucci E, Stampfer MJ, Colditz GA, Hunter DJ, Fuchs C, Rosner BA, Speizer FE, Willett WC. Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. *Ann Intern Med*. 1998 Oct 1;129(7):517-24.
191. Mayne ST, Risch HA, Dubrow R, Chow WH, Gammon MD, Vaughan TL, Farrow DC, Schoenberg JB, Stanford JL, Ahsan H, West AB, Rotterdam H, Blot WJ, Fraumeni JF Jr. Nutrient intake and risk of subtypes of esophageal and gastric cancer. *Cancer Epidemiol Biomarkers Prev*. 2001 Oct;10(10):1055-62.
192. Zhu S, Mason J, Shi Y, Hu Y, Li R, Wahg M, Zhou Y, Jin G, Xie Y, Wu G, Xia D, Qian Z, Sohng H, Zhang L, Russell R, Xiao S. The effect of folic acid on the development of stomach and other gastrointestinal cancers. *Chin Med J (Engl)*. 2003 Jan;116(1):15-9.
193. Jacques PF, Chylack LT Jr, Hankinson SE, Khu PM, Rogers G, Friend J, Tung W, Wolfe JK, Padhye N, Willett WC, Taylor A. Long-term nutrient intake and early age-related nuclear lens opacities. *Arch Ophthalmol*. 2001 Jul;119(7):1009-19.
194. Mangoni AA, Sherwood RA, Swift CG, Jackson SH. Folic acid enhances endothelial function and reduces blood pressure in smokers: a randomized controlled trial. *J Intern Med*. 2002 Dec;252(6):497-503.
195. Kendler BS. Nutritional strategies in cardiovascular disease control: an update on vitamins and conditionally essential nutrients. *Prog Cardiovasc Nurs*. 1999 Autumn;14(4):124-9.

196. Tonstad S, Refsum H, Ueland PM. Association between plasma total homocysteine and parental history of cardiovascular disease in children with familial hypercholesterolemia. *Circulation*. 1997 Sep 16;96(6):1803-8.
197. Schwartz SM, Siscovick DS, Malinow MR, Rosendaal FR, Beverly RK, Hess DL, Psaty BM, Longstreth WT Jr, Koepsell TD, Raghunathan TE, Reitsma PH. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. *Circulation*. 1997 Jul 15;96(2):412-7.
198. Neal B, MacMahon S, Ohkubo T, Tonkin A, Wilcken D; PACIFIC Study Group. Dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart disease. *Eur Heart J*. 2002 Oct;23(19):1509-15.
199. Hernandez-Diaz S, Martinez-Losa E, Fernandez-Jarne E, Serrano-Martinez M, Martinez-Gonzalez MA. Dietary folate and the risk of nonfatal myocardial infarction. *Epidemiology*. 2002 Nov;13(6):700-6.
200. Marcucci R, Zanazzi M, Bertoni E, Rosati A, Fedi S, Lenti M, Prisco D, Castellani S, Abbate R, Salvadori M. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients. *Transplantation*. 2003 May 15;75(9):1551-5.
201. McNulty H, Cuskelly GJ, Ward M. Response of red blood cell folate to intervention: implications for folate recommendations for the prevention of neural tube defects. *Am J Clin Nutr*. 2000;71(5 Suppl):1308S-1311S.
202. Kondo A, Kimura K, Isobe Y, Kamihira O, Matsuura O, Gotoh M, Okai I. Folic acid reduces risks of having fetus affected with neural tube defects: dietary food folate and plasma folate concentration. *Nippon Hinyokika Gakkai Zasshi*. 2003 Jul;94(5):551-9.
203. Bailey LB, Rampersaud GC, Kauwell GP. Folic acid supplements and fortification affect the risk for neural tube defects, vascular disease and cancer: evolving science. *J Nutr*. 2003 Jun;133(6):1961S-1968S.
204. Rosenberg KD, Gelow JM, Sandoval AP. Pregnancy intendedness and the use of periconceptual folic acid. *Pediatrics*. 2003 May;111(5 Part 2):1142-5.
205. Hernandez-Diaz S, Werler MM, Louik C, Mitchell AA. Risk of gestational hypertension in relation to folic acid supplementation during pregnancy. *Am J Epidemiol*. 2002 Nov 1;156(9):806-12.
206. Kauwell GP, Lippert BL, Wilsky CE, Herrlinger-Garcia K, Hutson AD, Theriaque DW, Rampersaud GC, Cerda JJ, Bailey LB. Folate status of elderly women following moderate folate depletion responds only to a higher folate intake. *J Nutr*. 2000 Jun;130(6):1584-90.
207. Elkin AC, Higham J. Folic acid supplements are more effective than increased dietary folate intake in elevating serum folate levels. *BJOG*. 2000 Feb;107(2):285-9.
208. Kiely M, Flynn A, Harrington KE, Robson PJ, O' Connor N, Hannon EM, O' Ben MM, Bell S, Strain JJ. The efficacy and safety of nutritional supplement use in a representative sample of adults in the North/South Ireland Food Consumption Survey. *Public Health Nutr*. 2001 Oct;4(5A):1089-97.

209. Oakley GP Jr, Adams MJ, Dickinson CM. More folic acid for everyone, now. *J Nutr.* 1996 Mar;126(3):751S-755S.
210. Brouwer DA, Welten HT, van Doormaal JJ, Reijngoud DJ, Muskiet FA. Recommended dietary allowance of folic acid is insufficient for optimal homocysteine levels. *Ned Tijdschr Geneeskd.* 1998 Apr 4;142(14):782-6.
211. Ames BN. Micronutrients prevent cancer and delay aging. *Toxicol Lett.* 1998 Dec 28;102-103:5-18.
212. Laszlo A, Schuler EA, Sallay E, Endreffy E, Somogyi C, Varkonyi A, Havass Z, Jansen KP, Wolf B. Neonatal screening for biotinidase deficiency in Hungary: clinical, biochemical and molecular studies. *J Inherit Metab Dis.* 2003;26(7):693-8.
213. Joshi S, al-Essa MA, Archibald A, Ozand PT. Biotinidase deficiency: a treatable genetic disorder in the Saudi population. *East Mediterr Health J.* 1999 Nov;5(6):1213-7.
214. Molteni C, Smit I, Mills J, Huskisson J. Nutritional status of patients in a long-stay hospital for people with mental handicap. *S Afr Med J.* 2000 Nov;90(11):1135-40.
215. Pomponio RJ, Coskun T, Demirkol M, Tokatli A, Ozalp I, Huner G, Baykal T, Wolf B. Novel mutations cause biotinidase deficiency in Turkish children. *J Inherit Metab Dis.* 2000 Mar;23(2):120-8.
216. Bonjour JP. Biotin in man' s nutrition and therapy -- a review. *Int J Vitam Nutr Res.* 1977;47(2):107-18.
217. Taitz LS, Leonard JV, Bartlett K. Longterm auditory and visual complications of biotinidase deficiency. *Early Hum Dev* 1985 Sep;11(34):32531.
218. Wastell HJ, Bartlett K, Dale G, Shein A. Biotinidase deficiency: a survey of 10 cases. *Arch Dis Child* 1988 Oct;63(10):12449.
219. Ames BN. A role for supplements in optimizing health: the metabolic tune-up. *Arch Biochem Biophys.* 2004 Mar 1;423(1):227-34.
220. Furukawa Y. Enhancement of glucoseinduced insulin secretion and modification of glucose metabolism by biotin. *Nippon rinsho (JAPAN)* Oct 1999, 57 (10) p22619.
221. Koutsikos D.; Fourtounas C.; Kapetanaki A.; Agroyannis B.; Tzanatos H.; Rammos G.; Kopelias I.; Bosiolis B.; Bovoleti O.; Darema M.; Sallum G. Oral glucose tolerance test after highdose i.v. biotin administration in normogluccemic hemodialysis patients. *Renal Failure.* 1996, 18/1 (131137).
222. *Med Hypotheses* 2000 Mar;54(3):4837.
223. Maebashi Masaru; Makino Yoshio; Furukawa Yuji(a); Ohinata Kosaku; Kimura Shuichi. Therapeutic evaluation of the effect of biotin on hyperglycemia in patients with noninsulin dependent diabetes mellitus. *Journal of Clinical Biochemistry and Nutrition* 1993 14 (3): p 211-218.

224. Med Hypotheses 2000 Mar;54(3):4837.
225. McCarty MF. Highdose biotin, an inducer of glucokinase expression, may synergize with chromium picolinate to enable a definitive nutritional therapy for type II diabetes. Medical hypotheses. May 1999, 52 (5) p4016.
226. McCarty M.F. Towards practical prevention of type 2 diabetes. Medical Hypotheses. 2000, 54/5 (786793).
227. Koutsikos D, Agroyannis B, Tzanatos Exarchou H. Biotin for diabetic peripheral neuropathy. Biomed Pharmacother 1990;44(10):5114.
228. Shelley WB, Shelley ED. Uncombable hair syndrome: observations on response to biotin and occurrence in siblings with ectodermal dysplasia. J Am Acad Dermatol. 1985 Jul;13(1):97-102.
229. Diet, Nutrition and the Prevention of Chronic Diseases. WHO Technical Report Series. Report of a Joint WHO/FAO Expert Consultation. Geneva 2003. p. 72.
230. Chapman KM, Ham JO, Pearlman RA. Longitudinal assessment of the nutritional status of elderly veterans. J Gerontol A Biol Sci Med Sci. 1996 Jul;51(4):B261-9.
231. Yin S, Su Y, Liu Q, Zhang M. Dietary status of preschool children from day-care kindergartens in six cities of China. Wei Sheng Yan Jiu. 2002 Oct;31(5):375-8.
232. Weinstein M, Babyn P, Zlotkin S. An orange a day keeps the doctor away: scurvy in the year 2000. Pediatrics. 2001 Sep;108(3):E55.
233. Hampl JS, Taylor CA, Johnston CS. Intakes of vitamin C, vegetables and fruits: which schoolchildren are at risk? J Am Coll Nutr. 1999 Dec;18(6):582-90.
234. Vannucchi H, da Cunha DF, Bernardes MM, Unamuno MR. Brasil. Serum levels of vitamin A, E, C and B2, carotenoid and zinc in hospitalized elderly patients. Rev Saude Publica. 1994 Apr;28(2):121-6.
235. Boulinguez S, Bouyssou-Gauthier M, De Vencay P, Bedane C, Bonnetblanc J. Scurvy presenting with ecchymotic purpura and hemorrhagic ulcers of the lower limbs. Ann Dermatol Venereol. 2000 May;127(5):510-2.
236. Werbach MR. Nutritional strategies for treating chronic fatigue syndrome. Altern Med Rev. 2000 Apr;5(2):93-108.
237. Dejmek J, Ginter E, Solansky I, Podrazilova K, Stavkova Z, Benes I, Sram RJ. Vitamin C, E and A levels in maternal and fetal blood for Czech and Gypsy ethnic groups in the Czech Republic. Int J Vitam Nutr Res. 2002 May;72(3):183-90.
238. Clow CL, Laberge C, Scriver CR. Neonatal hypertyrosinemia and evidence for deficiency of ascorbic acid in Arctic and subarctic peoples. Can Med Assoc J. 1975 Oct 4;113(7):624-6.
239. Sauberlich HE. Human requirements and needs. Vitamin C status: methods and findings. Ann N Y Acad Sci. 1975 Sep 30;258:438-50.

240. Dawson KP, Richardson WW, Orsborn CE. The leucocyte ascorbic acid levels of children in hospital. *N Z Med J.* 1977 Feb 23;85(582):141-3. 4.
241. Stephen R, Utecht T. Scurvy identified in the emergency department: a case report. *J Emerg Med.* 2001;21(3):235-237.
242. Tabet N, Mantle D, Walker Z, Orrell M. Endogenous antioxidant activities in relation to concurrent vitamins A, C, and E intake in dementia. *Int Psychogeriatr.* 2002 Mar;14(1):7-15.
243. Sudha K, Rao AV, Rao A. Oxidative stress and antioxidants in epilepsy. *Clin Chim Acta.* 2001 Jan;303(1-2):19-24.
244. Kharb S. Vitamin E and C in preeclampsia. *Eur J Obstet Gynecol Reprod Biol.* 2000 Nov;93(1):37-9.
245. Panburana P, Phuapradit W, Puchaiwatananon O. Antioxidant nutrients and lipid peroxide levels in Thai preeclamptic pregnant women. *J Obstet Gynaecol Res.* 2000 Oct;26(5):377-81.
246. Simon JA, Hudes ES. Serum ascorbic acid and gallbladder disease prevalence among US adults: the Third National Health and Nutrition Examination Survey (NHANES III). *Arch Intern Med.* 2000 Apr 10;160(7):931-6.
247. Suboticanec K, Folnegovic-Smalc V, Turcin R, Mestrovic B, Buzina R. Plasma levels and urinary vitamin C excretion in schizophrenic patients.
248. *Hum Nutr Clin Nutr.* 1986 Nov;40(6):421-8. Suboticanec K, Folnegovic-Smalc V, Korbar M, Mestrovic B, Buzina R. Vitamin C status in chronic schizophrenia. *Biol Psychiatry.* 1990 Dec 1;28(11):959-66.
249. Delpont R, Ubbink JB, Human JA, Becker PJ, Myburgh DP, Vermaak WJ. Antioxidant vitamins and coronary artery disease risk in South African males. *Clin Chim Acta.* 1998 Nov;278(1):55-60.
250. Singh RB, Ghosh S, Niaz MA, Singh R, Beegum R, Chibo H, Shoumin Z, Postiglione A. Dietary intake, plasma levels of antioxidant vitamins, and oxidative stress in relation to coronary artery disease in elderly subjects. *Am J Cardiol.* 1995 Dec 15;76(17):1233-8.
251. Singh RB, Niaz MA, Bishnoi I, Sharma JP, Gupta S, Rastogi SS, Singh R, Begum R, Chibo H, Shoumin Z. Diet, antioxidant vitamins, oxidative stress and risk of coronary artery disease: the Peerzada Prospective Study. *Acta Cardiol.* 1994;49(5):453-67.
252. Gey KF. Vitamins E plus C and interacting conutrients required for optimal health. A critical and constructive review of epidemiology and supplementation data regarding cardiovascular disease and cancer. *Biofactors.* 1998;7(1-2):113-74.
253. Akkus I, Saglam NI, Caglayan O, Vural H, Kalak S, Saglam M. Investigation of erythrocyte membrane lipid peroxidation and antioxidant defense systems of patients with coronary artery disease (CAD) documented by angiography. *Clin Chim Acta.* 1996 Jan 31;244(2):173-80.

254. Chen JH, Liu XJ, Wang QC, Zeng H, Jiang XP. Study on the changes in endogenous oxidation agents and levels of anti-oxidation agents in patients with cerebral vascular disease. *Zhongguo Wei Zhong Bing Ji Jiu Yi Xue*. 2003 Apr;15(4):232-4.
255. Skrzydlewska E, Kozusko B, Sulkowska M, Bogdan Z, Kozlowski M, Snarska J, Puchalski Z, Sulkowski S, Skrzydlewski Z. Antioxidant potential in esophageal, stomach and colorectal cancers. *Hepatogastroenterology*. 2003 Jan-Feb;50(49):126-31.
256. Beno I, Ondreicka R, Magalova T, Brtkova A, Grancicova E. Precancerous conditions and carcinomas of the stomach and colorectum--blood levels of selected micronutrients. *Bratisl Lek Listy*. 1997 Dec;98(12):674-7.
257. Choi MA, Kim BS, Yu R. Serum antioxidative vitamin levels and lipid peroxidation in gastric carcinoma patients. *Cancer Lett*. 1999 Feb 8;136(1):89-93.
258. Yokoyama T, Date C, Kokubo Y, Yoshiike N, Matsumura Y, Tanaka H. Serum vitamin C concentration was inversely associated with subsequent 20-year incidence of stroke in a Japanese rural community. The Shibata study. *Stroke*. 2000 Oct;31(10):2287-94.
259. You WC, Zhang L, Gail MH, Chang YS, Liu WD, Ma JL, Li JY, Jin ML, Hu YR, Yang CS, Blaser MJ, Correa P, Blot WJ, Fraumeni JF Jr, Xu GW. Gastric dysplasia and gastric cancer: *Helicobacter pylori*, serum vitamin C, and other risk factors. *J Natl Cancer Inst*. 2000 Oct 4;92(19):1607-12.
260. Kodama M, Kodama T. In search of the cause of gastric cancer. *In Vivo*. 2000 Jan-Feb;14(1):125-38.
261. Dabrowska-Ufniaz E, Dzieniszewski J, Jarosz M, Wartanowicz M. Vitamin C concentration in gastric juice in patients with precancerous lesions of the stomach and gastric cancer. *Med Sci Monit*. 2002 Feb;8(2):CR96-103.
262. Nishida M, Grossi SG, Dunford RG, Ho AW, Trevisan M, Genco RJ. Dietary vitamin C and the risk for periodontal disease. *J Periodontol*. 2000 Aug;71(8):1215-23.
263. Rath M, Pauling L. Solution to the puzzle of human cardiovascular disease: Its primary cause is ascorbate deficiency, leading to the deposition of lipoprotein (a) and fibrinogen/fibrin in the vascular wall. *Journal of Orthomolecular Medicine*. 1991; 6:125-134.
264. De Stefani E, Boffetta P, Brennan P, Deneo-Pellegrini H, Carzoglio JC, Ronco A, Mendilaharsu M. Dietary carotenoids and risk of gastric cancer: a case-control study in Uruguay. *Eur J Cancer Prev*. 2000 Oct;9(5):329-34.
265. La Vecchia C, D'Avanzo B, Negri E, Decarli A, Benichou J. Attributable risks for stomach cancer in northern Italy. *Int J Cancer*. 1995 Mar 16;60(6):748-52.
266. Ekstrom AM, Serafini M, Nyren O, Hansson LE, Ye W, Wolk A. Dietary antioxidant intake and the risk of cardia cancer and noncardia cancer of the intestinal and diffuse types: a population-based case-control study in Sweden. *Int J Cancer*. 2000 Jul 1;87(1):133-40.
267. Feiz HR, Mobarhan S. Does vitamin C intake slow the progression of gastric cancer in *Helicobacter pylori*-infected populations? *Nutr Rev*. 2002 Jan;60(1):34-6.

268. Valle J, Gisbert JP. Helicobacter pylori infection and precancerous lesions of the stomach. *Hepatogastroenterology*. 2001 Nov-Dec;48(42):1548-51.
269. Zhang L, Blot WJ, You WC, Chang YS, Liu XQ, Kneller RW, Zhao L, Liu WD, Li JY, Jin ML, et al. Serum micronutrients in relation to pre-cancerous gastric lesions. *Int J Cancer*. 1994 Mar 1;56(5):650-4.
270. Terry P, Lagergren J, Ye W, Nyren O, Wolk A. Antioxidants and cancers of the esophagus and gastric cardia. *Int J Cancer*. 2000 Sep 1;87(5):750-4.
271. Mirvish SS. Experimental evidence for inhibition of N-nitroso compound formation as a factor in the negative correlation between vitamin C consumption and the incidence of certain cancers. *Cancer Res*. 1994 Apr 1;54(7 Suppl):1948s-1951s.
272. Jacques PF, Chylack LT Jr, Hankinson SE, Khu PM, Rogers G, Friend J, Tung W, Wolfe JK, Padhye N, Willett WC, Taylor A. Long-term nutrient intake and early age-related nuclear lens opacities. *Arch Ophthalmol*. 2001 Jul;119(7):1009-19.
273. Jacques PF. The potential preventive effects of vitamins for cataract and age-related macular degeneration. *Int J Vitam Nutr Res*. 1999 May;69(3):198-205.
274. Brubaker RF, Bourne WM, Bachman LA, McLaren JW. Ascorbic acid content of human corneal epithelium. *Invest Ophthalmol Vis Sci*. 2000 Jun;41(7):1681-3.
275. Schindler TH, Lewandowski E, Olschewski M, Hasler K, Solzbach U, Just H. Effect of vitamin c on platelet aggregation in smokers and nonsmokers. *Med Klin*. 2002 May 15;97(5):263-9.
276. Osganian SK, Stampfer MJ, Rimm E, Spiegelman D, Hu FB, Manson JE, Willett WC. Vitamin C and risk of coronary heart disease in women. *J Am Coll Cardiol*. 2003 Jul 16;42(2):246-52.
277. Fang JC, Kinlay S, Beltrame J, Hikiti H, Wainstein M, Behrendt D, Suh J, Frei B, Mudge GH, Selwyn AP, Ganz P. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. *Lancet*. 2002 Mar 30;359(9312):1108-13.
278. Rath M, Pauling L. A unified theory of human cardiovascular disease leading the way to the abolition of this disease as a cause for human mortality. *Journal of Orthomolecular Medicine*. 1992; 7:5-15.
279. Rath M. Reducing the risk for cardiovascular disease with nutritional supplements. *Journal of Orthomolecular Medicine*. 1992; 7:153-162.
280. Rath M, Niedzwiecki A. Nutritional Supplement Program Halts Progression of Early Coronary Atherosclerosis Documented by Ultrafast Computed Tomography. *Journal of Applied Nutrition*. 1996; 48:68-78.
281. Salonen JT, Nyyssonen K, Salonen R, Lakka HM, Kaikkonen J, Porkkala-Sarataho E, Voutilainen S, Lakka TA, Rissanen T, Leskinen L, Tuomainen TP, Valkonen VP, Ristonmaa U, Poulsen HE. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. *J Intern Med*. 2000 Nov;248(5):377-86.

282. Brown DJ, Goodman J. A review of vitamins A, C, and E and their relationship to cardiovascular disease. *Clin Excell Nurse Pract.* 1998 Jan;2(1):10-22.
283. Rath M, Niedzwiecki A. Progression of early stages of coronary calcifications can be stopped by the synergistic effect of vitamins and essential nutrients. *Atherosclerosis.* 1997; 134:333.
284. Kendler BS. Nutritional strategies in cardiovascular disease control: an update on vitamins and conditionally essential nutrients. *Prog Cardiovasc Nurs.* 1999 Autumn;14(4):124-9.
285. Gey KF, Stahelin HB, Ballmer PE. Essential antioxidants in cardiovascular diseases--lessons for Europe. *Ther Umsch.* 1994 Jul;51(7):475-82.
286. Eichholzer M, Stahelin HB, Gey KF. Inverse correlation between essential antioxidants in plasma and subsequent risk to develop cancer, ischemic heart disease and stroke respectively: 12-year follow-up of the Prospective Basel Study. *EXS.* 1992;62:398-410.
287. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. *Epidemiology.* 1992 May;3(3):194-202.
288. Simon JA, Hudes ES, Tice JA. Relation of serum ascorbic acid to mortality among US adults. *J Am Coll Nutr.* 2001 Jun;20(3):255-63.
289. Sinatra ST, DeMarco J. Free radicals, oxidative stress, oxidized low density lipoprotein (LDL), and the heart: antioxidants and other strategies to limit cardiovascular damage. *Conn Med.* 1995 Oct;59(10):579-88.
290. Flagg EW, Coates RJ, Greenberg RS. Epidemiologic studies of antioxidants and cancer in humans. *J Am Coll Nutr.* 1995 Oct;14(5):419-27.
291. Block G. Epidemiologic evidence regarding vitamin C and cancer. *Am J Clin Nutr.* 1991 Dec;54(6 Suppl):1310S-1314S.
292. Kikuchi S. Epidemiology of *Helicobacter pylori* and gastric cancer. *Gastric Cancer.* 2002;5(1):6-15.
293. Mayne ST, Risch HA, Dubrow R, Chow WH, Gammon MD, Vaughan TL, Farrow DC, Schoenberg JB, Stanford JL, Ahsan H, West AB, Rotterdam H, Blot WJ, Fraumeni JF Jr. Nutrient intake and risk of subtypes of esophageal and gastric cancer. *Cancer Epidemiol Biomarkers Prev.* 2001 Oct;10(10):1055-62.
294. Hansson LE, Nyren O, Bergstrom R, Wolk A, Lindgren A, Baron J, Adami HO. Nutrients and gastric cancer risk. A population-based case-control study in Sweden. *Int J Cancer.* 1994 Jun 1;57(5):638-44.
295. Cohen M. Ascorbic acid and gastrointestinal cancer. *J Am Coll Nutr.* 1995 Dec;14(6):565-78.
296. Zhang L, Zhao L, Ma J. Relationship between serum micronutrients and precancerous gastric lesions. *Zhonghua Yu Fang Yi Xue Za Zhi.* 1995 Jul;29(4):198-201.

297. Lamm DL, Riggs DR, Shriver JS, vanGilder PF, Rach JF, DeHaven JI. Megadose vitamins in bladder cancer: a double-blind clinical trial. *J Urol.* 1994 Jan;151(1):21-6.
298. Do MH, Lee SS, Jung PJ, Lee MH. Intake of dietary fat and vitamin in relation to breast cancer risk in Korean women: a case-control study. *J Korean Med Sci.* 2003 Aug;18(4):534-40.
299. Zhang S, Hunter DJ, Forman MR, Rosner BA, Speizer FE, Colditz GA, Manson JE, Hankinson SE, Willett WC. Dietary carotenoids and vitamins A, C, and E and risk of breast cancer. *J Natl Cancer Inst.* 1999 Mar 17;91(6):547-56.
300. Van Hoydonck PG, Temme EH, Schouten EG. A dietary oxidative balance score of vitamin C, beta-carotene and iron intakes and mortality risk in male smoking Belgians. *J Nutr.* 2002 Apr;132(4):756-61.
301. Grzegorzczak K, Rutkowski M, Drozda R. Vitamin C in treatment of certain cardiovascular diseases. *Pol Merkuriusz Lek.* 2001 Feb;10(56):122-5.
302. Paolisso G, Balbi V, Volpe C, Varricchio G, Gambardella A, Saccomanno F, Ammendola S, Varricchio M, D' Orefrio F. Metabolic benefits deriving from chronic vitamin C supplementation in aged non-insulin dependent diabetics. *J Am Coll Nutr.* 1995 Aug;14(4):387-92.
303. Sargeant LA, Wareham NJ, Bingham S, Day NE, Luben RN, Oakes S, Welch A, Khaw KT. Vitamin C and hyperglycemia in the European Prospective Investigation into Cancer--Norfolk (EPIC-Norfolk) study: a population-based study. *Diabetes Care.* 2000 Jun;23(6):726-32.
304. Nathens AB, Neff MJ, Jurkovich GJ, Klotz P, Farver K, Ruzinski JT, Radella F, Garcia I, Maier RV. Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. *Ann Surg.* 2002 Dec;236(6):814-22.
305. Hajjar IM, George V, Sasse EA, Kochar MS. A randomized, double-blind, controlled trial of vitamin C in the management of hypertension and lipids. *Am J Ther.* 2002 Jul-Aug;9(4):289-93.
306. Brody S, Preut R, Schommer K, Schurmeyer TH. A randomized controlled trial of high dose ascorbic acid for reduction of blood pressure, cortisol, and subjective responses to psychological stress. *Psychopharmacology (Berl).* 2002 Jan;159(3):319-24. Epub 2001 Nov 20.
307. Sherman DL, Keaney JF Jr, Biegelsen ES, Duffy SJ, Coffman JD, Vita JA. Pharmacological concentrations of ascorbic acid are required for the beneficial effect on endothelial vasomotor function in hypertension. *Hypertension.* 2000 Apr;35(4):936-41.
308. Fotherby MD, Williams JC, Forster LA, Craner P, Ferns GA. Effect of vitamin C on ambulatory blood pressure and plasma lipids in older persons. *J Hypertens.* 2000 Apr;18(4):411-5.
309. Mullan BA, Young IS, Fee H, McCance DR. Ascorbic acid reduces blood pressure and arterial stiffness in type 2 diabetes. *Hypertension.* 2002 Dec;40(6):804-9.
310. Vitamins C and E levels greater than the RDA are associated with prevention of ovarian cancer. Fleischauer AT, Olson SH, Mignone L, Simonsen N, Caputo TA, Harlap S. Dietary antioxidants, supplements, and risk of epithelial ovarian cancer. *Nutr Cancer.* 2001;40(2):92-8.

311. Schaafsma A, de Vries PJ, Saris WH. Delay of natural bone loss by higher intakes of specific minerals and vitamins. *Crit Rev Food Sci Nutr*. 2001 May;41(4):225-49.
312. Morton DJ, Barrett-Connor EL, Schneider DL. Vitamin C supplement use and bone mineral density in postmenopausal women. *J Bone Miner Res*. 2001 Jan;16(1):135-40.
313. Melhus H, Michaelsson K, Holmberg L, Wolk A, Ljunghall S. Smoking, antioxidant vitamins, and the risk of hip fracture. *J Bone Miner Res*. 1999 Jan;14(1):129-35).
314. Hemila H. Vitamin c and the common cold. *Br J Nutr*. 1992 Jan;67(1):3-16. Van Straten M, Josling P. Preventing the common cold with a vitamin C supplement: a double-blind, placebo-controlled survey. *Adv Ther*. 2002 May-Jun;19(3):151-9.
315. Gorton HC, Jarvis K. The effectiveness of vitamin C in preventing and relieving the symptoms of virus-induced respiratory infections. *Manipulative Physiol Ther*. 1999 Oct;22(8):530-3.
316. Johnston CS, Cox SK. Plasma-Saturating intakes of vitamin C confer maximal antioxidant protection to plasma. *J Am Coll Nutr*. 2001 Dec;20(6):623-7.
317. Thompson D, Williams C, McGregor SJ, Nicholas CW, McArdle F, Jackson MJ, Powell JR. Prolonged vitamin C supplementation and recovery from demanding exercise. *Int J Sport Nutr Exerc Metab*. 2001 Dec;11(4):466-81.
318. Nieman DC, Peters EM, Henson DA, Nevines EI, Thompson MM. Influence of vitamin C supplementation on cytokine changes following an ultramarathon. *J Interferon Cytokine Res*. 2000 Nov;20(11):1029-35.
319. Romieu I, Trenga C. Diet and obstructive lung diseases. *Epidemiol Rev*. 2001;23(2):268-87.
320. Jacob RA. Passive smoking induces oxidant damage preventable by vitamin C. *Nutr Rev*. 2000 Aug;58(8):239-41.
321. Panda K, Chattopadhyay R, Chattopadhyay DJ, Chatterjee IB. Vitamin C prevents cigarette smoke-induced oxidative damage in vivo. *Free Radic Biol Med*. 2000 Jul 15;29(2):115-24.
322. Zhang J, Ying X, Lu Q, Kallner A, Xiu RJ, Henriksson P, Bjorkhem I. A single high dose of vitamin C counteracts the acute negative effect on microcirculation induced by smoking a cigarette. *Microvasc Res*. 1999 Nov;58(3):305-11.
323. Gamble J, Grewal PS, Gartside IB. Vitamin C modifies the cardiovascular and microvascular responses to cigarette smoke inhalation in man. *Clin Sci (Lond)*. 2000 Apr;98(4):455-60.
324. Rezaian GR, Taheri M, Mozaffari BE, Mosleh AA, Ghalambor MA. The salutary effects of antioxidant vitamins on the plasma lipids of healthy middle aged-to-elderly individuals: a randomized, double-blind, placebo-controlled study. *J Med Liban*. 2002 Jan-Apr;50(1-2):10-3.
325. J Dryburgh DR. Vitamin C and chiropractic. *Manipulative Physiol Ther*. 1985 Jun;8(2):95-103.

326. Henley S. Women on the pill are opening up a small case of side effects every morning. *Body Forum*. 1977 Jan 30;2(7):20.
327. Gorozhanskaia EG, Gromova EG, Sviridova SP. The role of ascorbic acid in the combined preoperative preparation of cancer patients. *Vopr Onkol*. 1989;35(4):436-41.
328. Sukolinskii VN, Morozkina TS. Prevention of postoperative complications in patients with stomach cancer using an antioxidant complex. *Vopr Onkol*. 1989;35(10):1242-5.
329. Engelhart MJ, Geerlings MI, Ruitenbergh A, van Swieten JC, Hofman A, Witteman JC, Breteler MM. Dietary intake of antioxidants and risk of Alzheimer disease. *JAMA*. 2002 Jun 26;287(24):3223-9.
330. Masaki KH, Losonczy KG, Izmirlian G, Foley DJ, Ross GW, Petrovitch H, Havlik R, White LR. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. *Neurology*. 2000 Mar 28;54(6):1265-72.
331. Grodstein F, Chen J, Willett WC. High-dose antioxidant supplements and cognitive function in community-dwelling elderly women. *Am J Clin Nutr*. 2003 Apr;77(4):975-84.
332. Diet, Nutrition and the Prevention of Chronic Diseases. WHO Technical Report Series. Report of a Joint WHO/FAO Expert Consultation. Geneva 2003. p. 81.
333. Parkin DM. Global cancer statistics in the year 2000. *Lancet Oncology*, 2001, 2:533-543.
334. Mezquita Raya P, Munoz Torres M, Lopez Rodriguez F, Martinez Martin N, Conde Valero A, Ortego Centeno N, Gonzalez Calvin J, Raya Alvarez E, Luna Jd Jde D, Escobar Jimenez F. Prevalence of vitamin D deficiency in populations at risk for osteoporosis: impact on bone integrity. *Med Clin (Barc)*. 2002 Jun 22;119(3):85-9.
335. Rodriguez-Martinez MA, Garcia-Cohen EC. Role of Ca(2+) and vitamin D in the prevention and treatment of osteoporosis. *Pharmacol Ther*. 2002 Jan;93(1):37-49.
336. Lilliu H, Pamphile R, Chapuy MC, Schulten J, Arlot M, Meunier PJ. Calcium-vitamin D3 supplementation is cost-effective in hip fractures prevention. *Maturitas*. 2003 Apr 25;44(4):299-305.
337. Pfeiffer. *J Bone Min Res*. 2000, 15:1113-6.
338. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial *BMJ* 2003;326:469-72.
339. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ. Vitamin D3 and calcium to prevent hip fractures in the elderly women. *N Engl J Med*. 1992; 327:1637-1642.
340. Dawson-Hughes B., Harris S. S., Krall E. A., Dallal G. E. Effect of Calcium and Vitamin D Supplementation on Bone Density in Men and Women 65 Years of Age or Older. *N Engl J Med* 1997; 337:670-676.

341. Fardellone P, Sebert JL, Garabedian M, Bellony R, Maamer M, Agbomson F, Brazie rM. Prevalence and biological consequences of vitamin D deficiency in elderly institutionalized subjects. *Rev Rhum Engl Ed.* 1995 Oct;62(9):576-81.
342. Markestad T. Effect of season and vitamin D supplementation on plasma concentrations of 25-hydroxyvitamin D in Norwegian infants. *Acta Paediatr Scand.* 1983 Nov;72(6):817-21.
343. Zamora SA, Rizzoli R, Belli DC, Slosman DO, Bonjour JP. Vitamin D supplementation during infancy is associated with higher bone mineral mass in prepubertal girls. *J Clin Endocrinol Metab.* 1999 Dec;84(12):4541-4.
344. Garland CF, Garland FC, Gorham ED. Calcium and vitamin D. Their potential roles in colon and breast cancer prevention. *Ann N Y Acad Sci.* 1999;889:107-19.
345. Peehl DM. Vitamin D and prostate cancer risk. *Eur Urol.* 1999;35(5-6):392-4.
346. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. *Lancet.* 2001 Nov 3;358(9292):1500-3.
347. Munger KL, Zhang SM, O'Reilly E, Hernan MA, Olek MJ, Willet WC, Ascherio A. Vitamin D intake and incidence of multiple sclerosis. *Neurology.* 2004 Jan 13;62(1):60-65.
348. Goldberg P, Fleming MC, Picard EH. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. *Med Hypotheses.* 1986 Oct;21(2):193-200.
349. Sasidharan PK, Rajeev E, Vijayakumari V. Tuberculosis and vitamin D deficiency. *J Assoc Physicians India.* 2002 Apr;50:554-8.
350. Bicknel F, Prescott F. *The Vitamins in Medicine*, third edition. Milwaukee, WI: Lee Foundation. 1953, p.544, 584-591.
351. Vieth, R. (1999). Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. *American Journal of Clinical Nutrition*, Vol. 69, No. 5, 842-856, May 1999.
352. Marya RK, Rathee S, Lata V, Mudgil S. Effects of vitamin D supplementation in pregnancy. *Gynecol Obstet Invest.* 1981;12(3):155-61.
353. Azen SP, Qian D, Mack WJ, et al. Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering. *Circulation.* 1996;94(10):2369-2372.
354. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). *Lancet.* 1996;347(9004):781-786.
355. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. *Lancet.* 2000;356(9237):1213-1218.

356. Williams SR. Nutrition and Diet Therapy, Seventh Edition. St. Louis: Mosby, 1993. (p 186). Sixth edition, 1989. (p 225).
357. Williams HTG, Fenna D, MacBeth RA. Alpha Tocopherol in the Treatment of Intermittent Claudication. *Surgery, Gynecology and Obstetrics* 132:#4, 662-666, April 1971.
358. Vasdev S, Gill V, Parai S, Longerich L, Gadag V. Dietary vitamin E supplementation lowers blood pressure in spontaneously hypertensive rats. *Mol Cell Biochem.* 2002 Sep; 238(1-2):111-7.
359. Vaziri ND, Ni Z, Oveisi F, Liang K, Pandian R. Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. *Hypertension.* 2002 Jan; 39(1):135-41.
360. Galley HF, Thornton J, Howdle PD, Walker BE, Webster NR. Combination oral antioxidant supplementation reduces blood pressure. *Clin Sci (Lond).* 1997 Apr;92(4):361-5.
361. Shute, Vogelsang, Skelton and Shute. *Surg., Gyn. and Obst.* 86:1. 1948.
362. Malmberg KJ, Lenkei R, Petersson M, Ohlum T, Ichihara F, Glimelius B, Frodin JE, Masucci G, Kiessling R. A short-term dietary supplementation of high doses of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal cancer. *Clin Cancer Res.* 2002 Jun; 8(6):1772-8.
363. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer' s disease. The Alzheimer's Disease Cooperative Study. *N Engl J Med.* Apr 24; 336(17):1216-22. 1997.
364. Ogunmekan AO, Hwang PA. A randomized, double-blind, placebo-controlled, clinical trial of D-alpha-tocopheryl acetate (vitamin E), as add-on therapy, for epilepsy in children. *Epilepsia.* 1989 Jan-Feb; 30(1):84-9.
365. Hittner HM, Godio LB, Rudolph AJ, Adams JM, Garcia-Prats JA, Friedman Z, Kautz JA, Monaco WA. Retrolental fibroplasia: efficacy of vitamin E in a double-blind clinical study of preterm infants. *N Engl J Med.* 1981 Dec 3; 305(23):1365-71.
366. Cheraskin E. Antioxidants in health and disease: the big picture. *Journal of Orthomolecular Medicine* 10: #2, 89-96, Second Quarter, 1995, citing Meydani, S.N., Barklund, M.P., Liu, S., Meydani, M., Miller, R.A., Cannon, J.G., Morrow, F.D., Rocklin, R., Blumberg, J.B. Effect of Vitamin E Supplementation on Immune Responsiveness of Healthy Elderly Subjects. *FASEB Journal* 3: A1057, 1989.
367. Meydani, S.N., Barklund, M.P., Liu, S., Meydani, M., Miller, R.A., Cannon, J.G., Morrow, F.D., Rocklin, R., Blumberg, J.B. Vitamin E supplementation enhances cell-mediated immunity in healthy elderly subjects. *American Journal of Clinical Nutrition* 52:#3, 557-563, September 1990.
368. *British Medical Journal*, i, 890, 1940 (cited in Bicknell & Prescott. *The vitamins in medicine.* Milwaukee: Lee Foundation, 1953, p 632).
369. Mecocci P, Polidori MC, Troiano L, Cherubini A, Cecchetti R, Pini G, Straatman M, Monti D, Stahl W, Sies H, Franceschi C, Senin U. Plasma antioxidants and longevity: a study on healthy centenarians. *Free Radic Biol Med.* 2000 Apr 15;28(8):1243-8.

370. Binkley NC, Krueger DC, Kawahara TN, Engelke JA, Chappell RJ, Suttie JW. A high phyloquinone intake is required to achieve maximal osteocalcin gamma-carboxylation. *Am J Clin Nutr*. 2002 Nov;76(5):1055-60.
371. Ferland G, Sadowski JA, O'Brien ME. Dietary induced subclinical vitamin K deficiency in normal human subjects. *J Clin Invest*. 1993 Apr;91(4):1761-8.
372. Bugel S. Vitamin K and bone health. *Proc Nutr Soc*. 2003 Nov;62(4):839-43.
373. Feskanich D, Weber P, Willett WC, Rockett H, Booth SL, Colditz GA. Vitamin K intake and hip fractures in women: a prospective study. *Am J Clin Nutr*. 1999;69(1):74-79.
374. Booth SL, Tucker KL, Chen H, et al. Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. *Am J Clin Nutr*. 2000;71(5):1201-1208.
375. Feskanich D, Weber P, Willett WC, Rockett H, Booth SL, Colditz GA. Vitamin K intake and hip fractures in women: a prospective study. *Am J Clin Nutr*. 1999 Jan;69(1):74-9.
376. Booth SL, Broe KE, Gagnon DR, Tucker KL, Hannan MT, McLean RR, Dawson-Hughes B, Wilson PW, Cupples LA, Kiel DP. Vitamin K intake and bone mineral density in women and men. *Am J Clin Nutr*. 2003 Feb;77(2):512-6.
377. Weber P. Management of osteoporosis: is there a role for vitamin K? *Int J Vitam Nutr Res*. 1997;67(5):350-6.
378. Ozuru R, Sugimoto T, Yamaguchi T, Chihara K. Time-dependent effects of vitamin K2 (menatetrenone) on bone metabolism in postmenopausal women. *Endocr J*. 2002 Jun;49(3):363-70.
379. Ushiroyama T, Ikeda A, Ueki M. Effect of continuous combined therapy with vitamin K(2) and vitamin D(3) on bone mineral density and coagulofibrinolysis function in postmenopausal women. *Maturitas*. 2002 Mar 25;41(3):211-21.
380. Iwamoto J, Takeda T, Ichimura S. Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis. *J Orthop Sci*. 2000;5(6):546-51.
381. Iketani T, Kiriike N, Murray, Stein B, Nagao K, Nagata T, Minamikawa N, Shidao A, Fukuhara H. Effect of menatetrenone (vitamin K2) treatment on bone loss in patients with anorexia nervosa. *Psychiatry Res*. 2003 Mar 25;117(3):259-69.
382. Sato Y, Honda Y, Kaji M, Asoh T, Hosokawa K, Kondo I, Satoh K. Amelioration of osteoporosis by menatetrenone in elderly female Parkinson's disease patients with vitamin D deficiency. *Bone*. 2002 Jul;31(1):114-8.
383. Durie PR. Vitamin K and the management of patients with cystic fibrosis. *CMAJ*. 1994 Oct 1;151(7):933-6.

384. Schoon EJ, Muller MC, Vermeer C, Schurgers LJ, Brummer RJ, Stockbrugger RW. Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease? *Gut*. 2001 Apr;48(4):473-7.
385. Malik S, Udani RH, Bichile SK, Agrawal RM, Bahrainwala AT, Tilaye S. Comparative study of oral versus injectable vitamin K in neonates. *Indian Pediatr*. 1992 Jul;29(7):857-9.
386. Isarangkura PB, Bintadish P, Tejavej A, Siripoonya P, Chulajata R, Green GM, Chalermchandra K. Vitamin K prophylaxis in the neonate by the oral route and its significance in reducing infant mortality and morbidity. *J Med Assoc Thai*. 1986 Oct;69 Suppl 2:56-61.
387. Olson JA. Recommended dietary intakes (RDI) of vitamin K in humans. *Am J Clin Nutr*. 1987 Apr;45(4):687-92.
388. Nishiguchi T, Yamashita M, Maeda M, Matsuyama K, Kobayashi T, Kanayama N, Terao T. Improvement of vitamin K status of breastfeeding infants with maternal supplement of vitamin K2 (MK40). *Semin Thromb Hemost*. 2002 Dec;28(6):533-8.
389. Jie KS, Bots ML, Vermeer C, Witteman JC, Grobbee DE. Vitamin K intake and osteocalcin levels in women with and without aortic atherosclerosis: a population-based study. *Atherosclerosis*. 1995;116(1):117-123.
390. Sakamoto N, Nishiike T, Iguchi H, Sakamoto K. Relationship between acute insulin response and vitamin K intake in healthy young male volunteers. *Diabetes Nutr Metab*. 1999 Feb;12(1):37-41.
391. Dietary Reference Intakes for Calcium, Phosphorous, Magnesium, Vitamin D, and Fluoride (1997).
392. Kaufman JM. Role of calcium and vitamin D in the prevention and the treatment of postmenopausal osteoporosis: an overview. *Clin Rheumatol*. 1995 Sep;14 Suppl 3:9-13.
393. Ma J, Betts NM. Zinc and copper intakes and their major food sources for older adults in the 1994-96 continuing survey of food intakes by individuals (CSFII). *J Nutr*. 2000 Nov;130(11):2838-43.
394. Swerts J, Benemariya H, Robberecht H, van Cauwenbergh R, Deelstra H. Daily dietary intake of copper and zinc by several population groups in Belgium: preliminary reports. *J Trace Elem Electrolytes Health Dis*. 1993 Sep;7(3):165-9.
395. Thomas AJ, Bunker VW, Hinks LJ, Sodha N, Mullee MA, Clayton BE. Energy, protein, zinc and copper status of twenty-one elderly inpatients: analysed dietary intake and biochemical indices. *Br J Nutr*. 1988 Mar;59(2):181-91.
396. Failla ML. Considerations for determining 'optimal nutrition' for copper, zinc, manganese and molybdenum. *Proc Nutr Soc*. 1999 May;58(2):497-505.
397. Williams DM. Copper deficiency in humans. *Semin Hematol*. 1983 Apr;20(2):118-28.
398. Holden JM, Wolf WR, Mertz W. Zinc and copper in self-selected diets. *J Am Diet Assoc*. 1979 Jul;75(1):23-8.

399. Alarcon OM, Guerrero Y, Ramirez de Fernandez M, D'Jesus I, Burguera M, Burguera JL, Di Bernardo ML. Effect of copper supplementation on blood pressure values in patients with stable moderate hypertension. *Arch Latinoam Nutr.* 2003 Sep;53(3):271-6.
400. Milne DB, Nielsen FH. Effects of a diet low in copper on copper-status indicators in postmenopausal women. *Am J Clin Nutr.* 1996 Mar;63(3):358-64.
401. Milne DB. Copper intake and assessment of copper status. *Am J Clin Nutr.* 1998 May;67(5 Suppl):1041S-1045S.
402. Aggett PJ. An overview of the metabolism of copper. *Eur J Med Res.* 1999 Jun 28;4(6):214-6.
403. Klevay LM. Lack of a recommended dietary allowance for copper may be hazardous to your health. *J Am Coll Nutr.* 1998 Aug;17(4):322-6.
404. Davydenko NV, Smirnova IP, Kvasha EA, Gorbas' IM. The relationship between the copper and zinc intake with food and the prevalence of ischemic heart disease and its risk factors. *Lik Sprava.* 1995 May-Jun;(5-6):73-7.
405. Saari JT, Schuschke DA. Cardiovascular effects of dietary copper deficiency. *Biofactors.* 1999;10(4):359-75.
406. Klevay LM. Ischemic heart disease. A major obstacle to becoming old. *Clin Geriatr Med.* 1987 May;3(2):361-72.
407. Klevay LM. Cardiovascular disease from copper deficiency--a history. *J Nutr.* 2000 Feb;130 (2S Suppl):489S-492S.
408. Chandra RK, Grace A. Goldsmith Award lecture. Trace element regulation of immunity and infection. *J Am Coll Nutr.* 1985;4(1):5-16.
409. Anderson RA. Chromium as an essential nutrient for humans. *Regul Toxicol Pharmacol.* 1997 Aug;26(1 Pt 2):S35-41.
410. Anderson RA. Chromium in the prevention and control of diabetes. *Diabetes Metab.* 2000 Feb;26(1):22-7.
411. Preuss HG, Anderson RA. Chromium update: examining recent literature 1997-1998. *Curr Opin Clin Nutr Metab Care.* 1998 Nov;1(6):509-12.
412. Anderson RA. Chromium metabolism and its role in disease processes in man. *Clin Physiol Biochem.* 1986;4(1):31-41.
413. Ding W, Chai Z, Duan P, Feng W, Qian Q. Serum and urine chromium concentrations in elderly diabetics. *Biol Trace Elem Res.* 1998 Sep;63(3):231-7.
414. Ravina A, Slezack L. Chromium in the treatment of clinical diabetes mellitus. *Harefuah.* 1993 Sep;125(5-6):142-5, 191.

415. Ghosh D, Bhattacharya B, Mukherjee B, Manna B, Sinha M, Chowdhury J, Chowdhury S. Role of chromium supplementation in Indians with type 2 diabetes mellitus. *J Nutr Biochem*. 2002 Nov;13(11):690-697.
416. Ryan GJ, Wanko NS, Redman AR, Cook CB. Chromium as adjunctive treatment for type 2 diabetes. *Ann Pharmacother*. 2003 Jun;37(6):876-85.
417. Morris BW, Kouta S, Robinson R, MacNeil S, Heller S. Chromium supplementation improves insulin resistance in patients with Type 2 diabetes mellitus. *Diabet Med*. 2000 Sep;17(9):684-5.
418. Bahijiri SM, Mira SA, Mufti AM, Ajabnoor MA. The effects of inorganic chromium and brewer's yeast supplementation on glucose tolerance, serum lipids and drug dosage in individuals with type 2 diabetes. *Saudi Med J*. 2000 Sep;21(9):831-7.
419. Anderson RA, Cheng N, Bryden NA, Polansky MM, Cheng N, Chi J, Feng J. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. *Diabetes*. 1997 Nov;46(11):1786-91.
420. Anderson RA. Chromium, glucose intolerance and diabetes. *J Am Coll Nutr*. 1998 Dec;17(6):548-55.
421. Anderson RA. Trace elements and cardiovascular diseases. *Acta Pharmacol Toxicol (Copenh)*. 1986;59 Suppl 7:317-24.
422. Mossop RT. Trivalent chromium, in atherosclerosis and diabetes. *Cent Afr J Med*. 1991 Nov;37(11):369-74.
423. Simonoff M. Chromium deficiency and cardiovascular risk. *Cardiovasc Res*. 1984 Oct;18(10):591-6.
424. Hansson L, Huunan-Seppala A, Mattila A. The content of calcium, magnesium, copper, zinc, lead and chromium in the blood of patients with rheumatoid arthritis. *Scand J Rheumatol*. 1975;4(1):33-8.
425. Davidson JR, Abraham K, Connor KM, McLeod MN. Effectiveness of chromium in atypical depression: a placebo-controlled trial. *Biol Psychiatry*. 2003 Feb 1;53(3):261-4.
426. Bahadori B, Wallner S, Schneider H, Wascher TC, Toplak H. Effect of chromium yeast and chromium picolinate on body composition of obese, non-diabetic patients during and after a formula diet. *Acta Med Austriaca*. 1997;24(5):185-7.
427. Crawford V, Scheckenbach R, Preuss HG. Effects of niacin-bound chromium supplementation on body composition in overweight African-American women. *Diabetes Obes Metab*. 1999 Nov;1(6):331-7.
428. Lamson DS, Plaza SM. The safety and efficacy of high-dose chromium. *Altern Med Rev*. 2002 Jun;7(3):218-35.
429. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc (2001). US National Academy of Science.

430. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc (2001). US National Academy of Science.
431. Magnesium Trace Elements 10: 162-28, 1997.
432. Sjogren, A., Edvinsson, L., and Fallgren, B. Magnesium deficiency in coronary artery disease and cardiac arrhythmias. *J Int Med*, 1989;226:213-22.
433. Dubey, A., and Solomon, R. Magnesium, Myocardial ischaemia and arrhythmias. The role of magnesium in myocardial infarction. *Drugs*, 1989;37:1-7.
434. Altura B. Magnesium in cardiovascular biology. *Scientific American* May/June 1995;28-35.
435. Turner RE, Langkamp-Henken B, Littell RC, Lukowski MJ, Suarez MF. Comparing nutrient intake from food to the estimated average requirements shows middle- to upper-income pregnant women lack iron and possibly magnesium. *J Am Diet Assoc*. 2003 Apr;103(4):461-6.
436. Vaquero MP. Magnesium and trace elements in the elderly: intake, status and recommendations. *J Nutr Health Aging*. 2002;6(2):147-53.
437. van der Sijs IH, Ho-Dac-Pannekeet MM. The treatment of hypomagnesemia. *Ned Tijdschr Geneesk*. 2002 May 18;146(20):934-8.
438. Milionis HJ, Alexandrides GE, Liberopoulos EN, Bairaktari ET, Goudevenos J, Elisaf MS. Hypomagnesemia and concurrent acid-base and electrolyte abnormalities in patients with congestive heart failure. *Eur J Heart Fail*. 2002 Mar;4(2):167-73.
439. Schimatschek HF, Rempis R. Prevalence of hypomagnesemia in an unselected German population of 16,000 individuals. *Magnes Res*. 2001 Dec;14(4):283-90.
440. Iannello S, Belfiore F. Hypomagnesemia. A review of pathophysiological, clinical and therapeutical aspects. *Panminerva Med*. 2001 Sep;43(3):177-209.
441. Deshmukh CT, Rane SA, Gurav MN. Hypomagnesaemia in paediatric population in an intensive care unit. *J Postgrad Med*. 2000 Jul-Sep;46(3):179-80.
442. Verive MJ, Irazuzta J, Steinhart CM, Orlowski JP, Jaimovich DG. Evaluating the frequency rate of hypomagnesemia in critically ill pediatric patients by using multiple regression analysis and a computer-based neural network. *Crit Care Med*. 2000 Oct;28(10):3534-9.
443. Fox CH, Ramsoomair D, Mahoney MC, Carter C, Young B, Graham R. An investigation of hypomagnesemia among ambulatory urban African Americans. *J Fam Pract*. 1999 Aug;48(8):636-9.
444. Faintuch JJ, Menezes MS. Magnesium and myocardial infarction. Brazilian aspects. *Rev Hosp Clin Fac Med Sao Paulo*. 1997 Nov-Dec;52(6):333-6.
445. Durlach J, Bac P, Durlach V, Rayssiguier Y, Bara M, Guiet-Bara A. Magnesium status and ageing: an update. *Magnes Res*. 1998 Mar;11(1):25-42.

446. Durlach J, Bac P, Durlach V, Durlach A, Bara M, Guiet-Bara A. Are age-related neurodegenerative diseases linked with various types of magnesium depletion? *Magnes Res.* 1997 Dec;10(4):339-53.
447. Singh RB, Rastogi V, Singh R, Niaz MA, Srivastav S, Aslam M, Singh NK, Moshir M, Postiglione A. Magnesium and antioxidant vitamin status and risk of complications of ageing in an elderly urban population. *Magnes Res.* 1996 Dec;9(4):299-306.
448. Singh RB, Rastogi V, Niaz MA, Sharma JP, Raghuvanshi R, Moshira M. Epidemiological study of magnesium status and risk of hypertension in a rural population of north India. *Magnes Res.* 1996 Oct;9(3):173-81.
449. Singh RB, Niaz MA, Ghosh S, Rastogi V, Raghuvanshi RS, Moshiri M. Epidemiological study of magnesium status and risk of coronary artery disease in elderly rural and urban populations of north India. *Magnes Res.* 1996 Oct;9(3):165-72.
450. Bondarev GI, Feoktistova AI, Zemlianskaia TA. Nutritional status of native and non-native population of Russia' s Extreme North and Far East. *Vopr Pitan.* 1993 Mar-Apr;(2):14-8.
451. Davydenko NV, Vasilenko IG. Magnesium level in food rations and the prevalence of ischemic heart disease among the population. *Gig Sanit.* 1991 May;(5):44-6.
452. Touitou Y, Godard JP, Ferment O, Chastang C, Proust J, Bogdan A, Auzéby A, Touitou C. Prevalence of magnesium and potassium deficiencies in the elderly. *Clin Chem.* 1987 Apr;33(4): 518-23.
453. Elin RJ. Magnesium metabolism in health and disease. *Dis Mon.* 1988 Apr;34(4):161-218.
454. Landon RA, Young EA. Role of magnesium in regulation of lung function. *J Am Diet Assoc.* 1993 Jun;93(6):674-7.
455. Rubeiz GJ, Thill-Baharozian M, Hardie D, Carlson RW. Association of hypomagnesemia and mortality in acutely ill medical patients. *Crit Care Med.* 1993 Feb;21(2):203-9.
456. Sherwood RA, Rocks BF, Stewart A, Saxton RS. Magnesium and the premenstrual syndrome. *Ann Clin Biochem.* 1986 Nov;23 (Pt 6):667-70.
457. Posaci C, Erten O, Uren A, Acar B. Plasma copper, zinc and magnesium levels in patients with premenstrual tension syndrome. *Acta Obstet Gynecol Scand.* 1994 Jul;73(6):452-5.
458. Britton J, Pavord I, Richards K, Wisniewski A, Knox A, Lewis S, Tattersfield A, Weiss S. Dietary magnesium, lung function, wheezing, and airway hyperreactivity in a random adult population sample. *Lancet.* 1994 Aug 6;344(8919):357-62.
459. Steidl L, Ditmar R. Blood magnesium findings in osteoporosis. *Acta Univ Palacki Olomuc Fac Med.* 1990;126:117-28.
460. Cohen L. Recent data on magnesium and osteoporosis. *Magnes Res.* 1988 Jul;1(1-2):85-7.

461. Driessens FC. Prevention of osteoporosis and pathological calcification. *Ned Tijdschr Tandheelkd.* 1993 Sep;100(9):412, 413-4.
462. Walti MK, Zimmermann MB, Spinaz GA, Hurrell RF. Low plasma magnesium in type 2 diabetes. *Swiss Med Wkly.* 2003 May 17;133(19-20):289-92.
463. Djurhuus MS, Klitgaard NA, Pedersen KK, Blaabjerg O, Altura BM, Altura BT, Henriksen JE. Magnesium reduces insulin-stimulated glucose uptake and serum lipid concentrations in type 1 diabetes. *Metabolism.* 2001 Dec;50(12):1409-17.
464. Naghii MR, Samman S. The role of boron in nutrition and metabolism. *Prog Food Nutr Sci.* 1993 Oct-Dec;17(4):331-49.
465. Devirian TA, Volpe SL. The physiological effects of dietary boron. *Crit Rev Food Sci Nutr.* 2003;43(2):219-31.
466. Nielsen FH, Hunt CD, Mullen LM, Hunt JR. Effect of dietary boron on mineral, estrogen, and testosterone metabolism in postmenopausal women. *FASEB J.* 1987 Nov;1(5):394-7.
467. Nielsen FH. Studies on the relationship between boron and magnesium which possibly affects the formation and maintenance of bones. *Magnes Trace Elem.* 1990;9(2):61-9.
468. Naghii MR, Samman S. The effect of boron supplementation on its urinary excretion and selected cardiovascular risk factors in healthy male subjects. *Biol Trace Elem Res.* 1997 Mar;56(3):273-86.
469. Penland JG. Dietary boron, brain function, and cognitive performance. *Environ Health Perspect.* 1994 Nov;102 Suppl 7:65-72.
470. Newnham RE. Essentiality of boron for healthy bones and joints. *Environ Health Perspect.* 1994 Nov;102 Suppl 7:83-5.
471. Zhang Z-F, Winton MI, Rainey C, et al: Boron is associated with decreased risk of human prostate cancer. *FASEB J* 15:A1089, 2001.
472. Feskanich D, Willett WC, Stampfer MJ, Colditz GA. Protein consumption and bone fractures in women. *Am J Epidemiol* 1996;143:472-9.
473. Raloff J. Reasons for boning up on manganese. *Science News* 1986;Sep 27:199 [review].
474. Gold M. Basketball bones. *Science* 1980;80:101-2.
475. Strause L, Saltman P, Smith KT, et al. Spinal bone loss in postmenopausal women supplemented with calcium and trace minerals. *J Nutr* 1994;124:1060-4.
476. Kosenko LG. Concentration of trace elements in the blood of patients with diabetes mellitus. *Fed Proc Transl (Suppl)* 1965;24:237-8.
477. Baly DL, Schneiderman JS, Garcia-Welsh AL. Effect of manganese deficiency on insulin binding, glucose transport and metabolism in rat adipocytes. *J Nutr* 1990;120:1075-9.

478. Kunin RA. Manganese in dyskinesias. *Am J Psychiatry* 1976;133:105.
479. Norris JP, Sams RE. More on the use of manganese in dyskinesia. *Am J Psychiatry* 1997;134:1448.
480. Hoffer A. Tardive dyskinesia treated with manganese. *Can Med Assoc J* 1977;117:859.
481. Balch and Balch, *Prescription for Nutritional Healing*, p 239-240.
482. Kimura M, Itokawa Y. Cooking losses of minerals in foods and its nutritional significance. *J Nutr Sci Vitaminol (Tokyo)* 1990;36:S25–33.
483. Pennington JAT. *Bowes and Church's Food Values of Portions Commonly Used*, 17th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 1997.
484. Davis CD, Malecki EA, Gerger JL. Interactions among dietary manganese, heme iron, and nonheme iron in women. *Am J Clin Nutr* 1992;56:926–32.
485. Barceloux DG. Molybdenum. *J Toxicol Clin Toxicol.* 1999;37(2):231-7.
486. Sardesai VM. Molybdenum: an essential trace element. *Nutr Clin Pract* 1993;8:277–81.
487. Kibblewhite MG, Van Rensburg SJ, Laker MC, Rose EF. Evidence for an intimate geochemical factor in the etiology of esophageal cancer. *Environ Res.* 1984 Apr;33(2):370-8.
488. Tuyns AJ, Pequignot G, Jensen OM. Nutrition, alcohol and oesophageal cancer. *Bull Cancer.* 1978;65(1):58-64.
489. Nakadaira H, Endoh K, Yamamoto M, Katoh K. Distribution of selenium and molybdenum and cancer mortality in Niigata, Japan. *Arch Environ Health.* 1995 Sep-Oct;50(5):374-80.
490. Johnson JL, Wuebbens MM, Mandell R, Shih VE. Molybdenum cofactor deficiency in a patient previously characterized as deficient in sulfite oxidase. *Biochem Med Metabol Biol* 1988;40:86–93.
491. Moss M. Effects of molybdenum on pain and general health: a pilot study. *J Nutr Environ Med* 1995;5:55–61.
492. Yao ZM, Zhang LH. Microelement-molybdenum and its use for the treatment of children's fluorine-stained teeth. *Zhonghua Yu Fang Yi Xue Za Zhi.* 1992 Jan;26(1):28-31.
493. Murphy J, Hannon EM, Kiely M, Flynn A, Cashman KD. Selenium intakes in 18-64-y-old Irish adults. *Eur J Clin Nutr.* 2002 May;56(5):402-8.
494. Tutel' an VA, Khotimchenko SA. Selenium as an essential and deficient factor in the nutrition of Russian population. *Vestn Ross Akad Med Nauk.* 2001;(6):31-4.
495. Kvicala J, Zamrazil V, Jiranek V. Characterization of selenium status of inhabitants in the region Usti nad Orlici, Czech Republic by INAA of blood serum and hair and fluorimetric analysis of urine. *Biol Trace Elem Res.* 1999 Winter;71-72:31-9.

496. Kvicala J, Zamrazil V, Cerovska J, Bednar J, Janda J. Evaluation of selenium supply and status of inhabitants in three selected rural and urban regions of the Czech Republic. *Biol Trace Elem Res.* 1995 Jan-Mar;47(1-3):365-75.
497. Bogye G, Feher J, Georg A, Antti A. Relationship between selenium deficiency and high mortality and morbidity of cardiovascular diseases. *Orv Hetil.* 1994 Jan 16;135(3):115-8.
498. Sluis KB, Darlow BA, George PM, Mogridge N, Dolamore BA, Winterbourn CC. Selenium and glutathione peroxidase levels in premature infants in a low selenium community (Christchurch, New Zealand). *Pediatr Res.* 1992 Aug;32(2):189-94.
499. Maksimovic ZJ, Djujic I, Jovic V, Rsumovic M. Selenium deficiency in Yugoslavia. *Biol Trace Elem Res.* 1992 Apr-Jun;33:187-96.
500. Kivela SL, Maenpaa P, Nissinen A, Alfthan G, Punsar S, Enlund H, Puska P. Vitamin A, vitamin E and selenium status in an aged Finnish male population. *Int J Vitam Nutr Res.* 1989;59(4):373-80.
501. Wasowicz W, Zachara BA. Selenium concentrations in the blood and urine of a healthy Polish sub-population. *J Clin Chem Clin Biochem.* 1987 Jul;25(7):409-12.
502. Maksimovic Z, Djujic I. Selenium research in Serbia, Yugoslavia. *J Environ Pathol Toxicol Oncol.* 1998;17(3-4):165-71.
503. Kim YS, Milner J. Molecular targets for selenium in cancer prevention. *Nutr Cancer.* 2001;40(1):50-4.
504. Yu, Shu-Yu et al. Regional variation of cancer mortality incidence and its relation to selenium levels in China. *Biol. Trace Elem res.* 7:21-29, 1985.
505. Burguera JL, Burguera M, Galignani M, Alarcon OM, Burguera JA. Blood serum selenium in the province of Merida, Venezuela, related to sex, cancer incidence and soil selenium content. *J Trace Elem Electrolytes Health Dis* 1990 Jun;4(2):73-7.
506. Schrauzer GN. *Bioinorg Chem* 1976;5(3):275-81. Selenium and cancer: a review.
507. Shamberger RJ, Frost DV. Possible protective effect of selenium against human cancer. *Can Med Assoc J.* 1969 Apr 12;100(14):682.
508. Shamberger, R. J., and C. E. Willis. 1971. Selenium distribution and human cancer mortality. *CRC Crit. Rev. Clin. Lab. Sci.* 2:211-221.
509. Shamberger, R. J., S. A. Tytko, and C. E. Willis. 1976. Antioxidants and cancer. Part VI. Selenium and age-adjusted human cancer mortality. *Arch. Environ. Health* 31:231-235.
510. Clark LC. The epidemiology of selenium and cancer. *Fed Proc* 1985 Jun;44(9):2584-9.
511. Shrauzer GN, White DA, Schneider CJ. *Bioinorg Chem* 1977;7(1):23-31 Cancer mortality correlation studies--III: statistical associations with dietary selenium intakes.

512. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF Jr, Slate EH, Fischbach LA, Marshall JR, Clark LC. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. *Cancer Epidemiol Biomarkers Prev.* 2002 Jul;11(7):630-9.
513. Combs GF Jr, Clark LC, Turnbull BW. Reduction of cancer mortality and incidence by selenium supplementation. *Med Klin (Munich).* 1997 Sep 15;92 Suppl 3:42-5.
514. Li WG. Preliminary observations on effect of selenium yeast on high risk populations with primary liver cancer. *Zhonghua Yu Fang Yi Xue Za Zhi.* 1992 Sep;26(5):268-71.
515. Helzlsouer KJ, Huang HY, Alberg AJ, Hoffman S, Burke A, Norkus EP, Morris JS, Comstock GW. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. *J Natl Cancer Inst.* 2000 Dec 20;92(24):2018-23.
516. Nelson MA, Porterfield BW, Jacobs ET, Clark LC. Selenium and prostate cancer prevention. *Semin Urol Oncol.* 1999 May;17(2):91-6.
517. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Leshner JL Jr, Park HK, Sanders BB Jr, Smith CL, Taylor JR. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. *JAMA.* 1996;276:1957-1963.
518. Moore JA, Noiva R, Wells IC. Selenium concentrations in plasma of patients with arteriographically defined coronary atherosclerosis. *Clin Chem.* 1984 Jul;30(7):1171-3.
519. Oster O, Drexler M, Schenk J, Meinertz T, Kasper W, Schuster CJ, Prellwitz W. The serum selenium concentration of patients with acute myocardial infarction. *Ann Clin Res.* 1986;18(1):36-42.
520. Kok FJ, Hofman A, Witteman JC, de Bruijn AM, Kruyssen DH, de Bruin M, Valkenburg HA. Decreased selenium levels in acute myocardial infarction. *JAMA.* 1989 Feb 24;261(8):1161-4.
521. Salonen JT, Alfthan G, Huttunen JK, Pikkarainen J, Puska P. Association between cardiovascular death and myocardial infarction and serum selenium in a matched-pair longitudinal study. *Lancet.* 1982 Jul 24;2(8291):175-9.
522. Cowgill UM. The distribution of selenium and mortality owing to acquired immune deficiency syndrome in the continental United States. *Biol Trace Elem Res.* 1997 Jan;56(1):43-61.
523. Burbano X, Miguez-Burbano MJ, McCollister K, Zhang G, Rodriguez A, Ruiz P, Lecusay R, Shor-Posner G. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV-infected participants. *HIV Clin Trials.* 2002 Nov-Dec;3(6):483-91.
524. Borner J, Zimmermann T, Albrecht S, Roesner D. Selenium administration in children with SIRS. *Med Klin (Munich).* 1999 Oct 15;94 Suppl 3:93-6.
525. Bowrey DJ, Morris-Stiff GJ, Puntis MC. Selenium deficiency and chronic pancreatitis: disease mechanism and potential for therapy. *HPB Surg.* 1999;11(4):207-15; discussion 215-6.

526. Kurihara M, Kumagai K, Nakae Y, Nishino I, Nonaka I. Two sibling patients with non-Fukuyama type congenital muscular dystrophy with low serum selenium levels--therapeutic effects of oral selenium administration. *No To Hattatsu*. 2000 Jul;32(4):346-51.
527. Gazdik F, Horvathova M, Gazdikova K, Jahnova E. The influence of selenium supplementation on the immunity of corticoid-dependent asthmatics. *Bratisl Lek Listy*. 2002;103(1):17-21.
528. Bonomini M, Forster S, De Risio F, Rychly J, Nebe B, Manfrini V, Klinkmann H, Albertazzi A. Effects of selenium supplementation on immune parameters in chronic uraemic patients on haemodialysis. *Nephrol Dial Transplant*. 1995;10(9):1654-61.
529. Aydin K, Kendirci M, Kurtoglu S, Karakucuk EI, Kiris A. Iodine and selenium deficiency in school-children in an endemic goiter area in Turkey. *J Pediatr Endocrinol Metab*. 2002 Jul-Aug;15(7):1027-31.
530. Keskes-Ammar L, Feki-Chakroun N, Rebai T, Sahnoun Z, Ghazzi H, Hammami S, Zghal K, Fki H, Damak J, Bahloul A. Sperm oxidative stress and the effect of an oral vitamin E and selenium supplement on semen quality in infertile men. *Arch Androl*. 2003 Mar-Apr;49(2):83-94.
531. Scott R, MacPherson A, Yates RW, Hussain B, Dixon J. The effect of oral selenium supplementation on human sperm motility. *Br J Urol*. 1998 Jul;82(1):76-80.
532. Benton D, Cook R. The impact of selenium supplementation on mood. *Biol Psychiatry*. 1991 Jun 1;29(11):1092-8.
533. Benton D, Cook R. Selenium supplementation improves mood in a double-blind crossover trial. *Psychopharmacology (Berl)*. 1990;102(4):549-50.
534. Foster HD, Zhang L. Longevity and selenium deficiency: evidence from the People's Republic of China. *Sci Total Environ*. 1995 Aug 18;170(1-2):133-9.
535. Laryea MD, Schnittert B, Kersting M, Wilhelm M, Lombeck I. Macronutrient, copper, and zinc intakes of young German children as determined by duplicate food samples and diet records. *Ann Nutr Metab*. 1995;39(5):271-8.
536. Worwag M, Classen HG, Schumacher E. Prevalence of magnesium and zinc deficiencies in nursing home residents in Germany. *Magnes Res*. 1999 Sep;12(3):181-9.
537. Olivares M, Pizarro F, de Pablo S, Araya M, Uauy R. Iron, zinc, and copper: contents in common Chilean foods and daily intakes in Santiago, Chile. *Nutrition*. 2004 Feb;20(2):205-12.
538. Prasad AS. Zinc deficiency in women, infants and children. *J Am Coll Nutr*. 1996 Apr;15(2):113-20.
539. Hambidge KM. Zinc deficiency in man: its origins and effects. *Philos Trans R Soc Lond B Biol Sci*. 1981 Aug 14;294(1071):129-44.
540. Lemasters GK. Zinc insufficiency during pregnancy. A review. *JOGN Nurs*. 1981 Mar-Apr;10(2):124-5. (396).

541. Anetor JI, Senjobi A, Ajose OA, Agbedana EO. Decreased serum magnesium and zinc levels: atherogenic implications in type-2 diabetes mellitus in Nigerians. *Nutr Health*. 2002;16(4): 291-300.
542. Gupta R, Garg VK, Mathur DK, Goyal RK. Oral zinc therapy in diabetic neuropathy. *J Assoc Physicians India*. 1998 Nov;46(11):939-42.
543. Wellinghausen N, Kern WV, Jochle W, Kern P. Zinc serum level in human immunodeficiency virus-infected patients in relation to immunological status. *Biol Trace Elem Res* 2000 Feb;73(2): 139-49.
544. Baum MK, Campa A, Lai S, Lai H, Page JB. Zinc status in human immunodeficiency virus type 1 infection and illicit drug use. *Clin Infect Dis*. 2003;37 Suppl 2:S117-23.
545. Bergomi M, Rovesti S, Vinceti M, Vivoli R, Caselgrandi E, Vivoli G. . Zinc and copper status and blood pressure. *J Trace Elem Med Biol*. 1997 Nov;11(3):166-9.
546. Gur G; Bayraktar Y; Ozer D; Ozdogan M; Kayhan B. Determination of hepatic zinc content in chronic liver disease due to hepatitis B virus. *Hepatogastroenterology (Greece)* Mar-Apr 1998, 45 (20) p472-6.
547. Marchesini G; Bugianesi E; Ronchi M; Flaminia R; Thomasset K; Pacini G. Zinc supplementation improves glucose disposal in patients with cirrhosis. *Metabolism* Jul 1998, 47 (7) p792-8.
548. Reunanen A; Knekt P; Marniemi J; Maki J; Maatela J; Aromaa A. Serum calcium, magnesium, copper and zinc and risk of cardiovascular death. *Eur J Clin Nutr*. Jul 1996, 50 (7) p431-7.
549. Elmstahl S, Gullberg B, Janzon L, Johnell O, Elmstahl B. Increased incidence of fractures in middle-aged and elderly men with low intakes of phosphorus and zinc. *Osteoporos Int*. 1998;8(4): 333-40.
550. Forsleff L, Schauss AG, Bier ID, Stuart S. Evidence of functional zinc deficiency in Parkinson's disease. *J Altern Complement Med*. 1999 Feb;5(1):57-64.
551. Ochi K, Ohashi T, Kinoshita H, Akagi M, Kikuchi H, Mitsui M, Kaneko T, Kato I. The serum zinc level in patients with tinnitus and the effect of zinc treatment. *Nippon Jibiinkoka Gakkai Kaiho* 1997 Sep;100(9):915-9.
552. Arda HN, Tuncel U, Akdogan O, Ozluoglu LN. The role of zinc in the treatment of tinnitus. *Otol Neurotol*. 2003 Jan;24(1):86-9.
553. Di Toro R, Galdo Capotorti G, Gialanella G, Miraglia del Giudice M, Moro R, Perrone L. Zinc and copper status of allergic children. *Acta Paediatr Scand*. 1987 Jul;76(4):612-7.
554. Michaelsson G, Vahlquist A, Juhlin L. Serum zinc and retinol-binding protein in acne. *Br J Dermatol* 1977 Mar;96(3):283-6.
555. Michaelsson G, Juhlin L, Vahlquist A. Effects of oral zinc and vitamin A in acne. *Arch Dermatol* 1977 Jan;113(1):31-6.

556. Duchateau J, Delepesse G, Vrijens R, Collet H. Beneficial effects of oral zinc supplementation on the immune response of old people. *Am J Med* 1981 May;70(5):1001-4.
557. Mocchegiani E, Muzzioli M, Giacconi R. Zinc and immunoresistance to infection in aging: new biological tools. *Trends Pharmacol Sci*. 2000 Jun;21(6):205-8.
558. Newsome DA, Swartz M, Leone NC, Elston RC, Miller E. Oral zinc in macular degeneration. *Arch Ophthalmol*. 1988 Feb;106(2):192-8.
559. Liang JY, Liu YY, Zou J, Franklin RB, Costello LC, Feng P. Inhibitory effect of zinc on human prostatic carcinoma cell growth. *Prostate*. 1999 Aug 1;40(3):200-7.
560. Mossad SB; Macknin ML; Medendorp SV; Mason P. Zinc gluconate lozenges for treating the common cold. A randomized, double-blind, placebo-controlled study. *Ann Intern Med*. Jul 15 1996, 125 (2) p81-8.
561. The world health report 1998. Life in the 21st century: a vision for all. Geneva, World Health Organization, 1998.
562. JAMA. Vitamins for Chronic Disease Prevention in Adults. 2002;287:3127-3129.
563. NEJM. Editorial: Eat Right and Take a Multivitamin. Volume 338:1060-1061; April 9, 1998; Number 15.
564. *Public Health Nutr*. 2001 Oct;4(5A):1089-97. The efficacy and safety of nutritional supplement use in a representative sample of adults in the North/South Ireland Food Consumption Survey. Kiely M, Flynn A, Harrington KE, Robson PJ, O' Connor N, Hannon EM, O'Brien MM, Bell S, Strain JJ.